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Resume: 
 
 
Contexte: 
 
Le cancer colo-rectal est la deuxième cause de décès, par ordre de fréquence. 
L’utilisation de l’imagerie dans la stadification du cancer colo-rectal est un élément 
important de la prise en charge de la maladie. L’échographie endoscopique est une 
modalité qui permet de préciser la profondeur de l’atteinte néoplasique. Les données 
probantes concernant la performance diagnostique dans l’identification de cancers peu 
avancés sont variables. 
 
Objectif : 
 
Effectuer une revue systématique sur la performance diagnostique de l’échographie 
endoscopique dans l’identification de cancer de stade T1 et T2. 
 
Devis :  
 
Revue systématique. 
 
Sources bibliographiques : 
 
PubMed, EMBASE, Ovid and Cochrane library 
 
Méthodes: 
 
Dans un premier temps, une recherche de revue systématique publiée dans les 15 
dernières années fût effectuée sur la précision diagnostique de l’échographie 
endoscopique dans les banques PubMed, Cochrne et trip database. Deux revues 
systématiques, publiées en 2008 et 2009 fûrent identifiées. Une deuxième recherche 
portant sur des études primaires a été effectuée pour la période 2009 à 2016, dans les 
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mêmes banques bibliographiques. La qualité des études primaires a été évaluée à l’aide 
de la grille QUADAS2. Les mots clés utilisés étaient échographie endoscopique, EUS, 
cancer rectal, histo-pathologie, staging. 
Sélection d’études : 
 
Les critères d’inclusion : population adulte avec diagnostic de cancer du rectum pas 
avancé, articles complets publiés dans des revues avec comité de pairs, articles en 
anglais. Critères d’exclusion : population pédiatrique, cancers avancés avec atteinte 
métastatique, patients évalués avec d’autres modalités (CT ou IRM) sans échographie 
endoscopique, absence de confirmation histologique. 
 
Résultats : 
 
Dix articles, publiés depuis 2009, répondaient aux critères d’inclusion. Ces articles furent 
ajoutés aux articles retenus dans les revues systématiques déjà publiées. Au total,49  
articles sont inclus dans cette revue systématique. La performance diagnostique de 
l’échographie endoscopique a été évaluée en calculant la sensitivité et la spécificité des 
études regroupées. Pour le stade T1, les valeurs de sensitivité et spécificité étaient 0.84  
(CI 0.75-0.91) et 0.93 (CI 0.86–0.97), respectivement. Pour le stade T2 les valeurs de 
sensitivité et spécificité étaient 0.83 (CI 0.74–0.90) et 0.93 (CI 0.86–0.97), 
respectivement. 
Conclusion: 
 
L’échographie endoscopique présente une performance diagnostique pour l’identification 
de cancers de stade T1 et T2. Ceci permet d’orienter des patients vers des chirurgies 
moins invasives avec une survie égale et un taux de complications inférieures 
comparativement à des chirurgies plus invasives. 
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Abstract 
 
Background: 
Colorectal cancer (CRC) is the second leading cause of death. The use of preoperative 
imaging in the staging of (CRC) plays a major role in the management. 
Endorectal ultrasound (ERUS) is a precise imaging modality to determine the depth of 
penetration. The data on the precision of (ERUS) to predict early stage of rectal cancer 
has been variable 
Objectives: 
To conduct a systematic review, on the diagnostic performance of (ERUS) in the staging 
of T1 and T2 CRC. 
Design: 
Systematic review. 
Data sources: 
A literature search via PubMed, EMBASE, Ovid and Cochrane library. 
METHODS: 
An initial search for systematic review articles published in the last 15 years on the 
diagnostic accuracy of EUS in the staging of CRC using PubMed, Cochrane library, and 
trip database was conducted. After finding two systematic reviews that were published in 
2008 and 2009, a second search of original studies published since the systematic reviews 
were conducted using the same databases from 2009 to 2016. The primary studies 
included in the systematic reviews and the primary studies published afterwards were 
included in the review.  
Methodological quality was applied using a modified version of the quality assessment of 
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diagnostic accuracy studies (QUADAS2) tool.  
Terms used for search were endoscopic ultrasound, EUS, rectal cancer, histo-pathological 
finding, and staging.  
Study selection: 
Inclusion criteria includes adult people diagnosed with early stage CRC, all articles in 
english language and must be a full manuscripts published in peer-reviews journals. 
Exclusion criteria includes any recurrent or metastasis cancer and children with rectal 
cancer. Patients who were staged preoperatively by other imaging modality (MRI or CT) 
and no comparison with post operative pathology. 
Results:  
The search identified 420 articles, 97 articles were duplicate and excluded, and 232 
refined articles were screened for title and abstract, reviewed. Thirty-two full text studies 
were assessed for eligibility, and ten published as full text and met the inclusion criteria; 
they were added to the articles identified in the earlier systematic reviews a total of 49 
articles. Results of the evaluation of the accuracy of ERUS analyzed according to the 
diagnostic measures of sensitivities and specificities calculated for each study. 
The pooled sensitivity and specificity of EUS for stage T1 CRC was 0.84  (CI 0.75-0.91) 
and 0.93 (CI 0.86–0.97), and for T2 was 0.83 (CI 0.74–0.90) and 0.93(CI 0.86–0.97) 
respectively. 
Conclusion: 
The range of sensitivity and specificity values suggest that EUS performs well in 
accurately staging T1 and T2 cancers.  
Further advancement in this technology will lead to an improved diagnosis, clinical 
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decision-making, and reduce the over staging drawback. 
 
Keywords: Endorectal ultrasonography,rectal cancer,cancer staging,diagnostic accuracy 
endorectal echography,sensitivity and specificity, rectum carcinoma,rectum tumor 
histopathology and early staging 
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Chapter I                                       
Introduction 
1.1-Description of the condition: 
Colorectal cancer (CRC) is a common cancer and is considered the second most 
diagnosed cancer in the world [1]. 
The incidence rate increases with age and peaks in the seventh decade of life (mean age 
60-65 years). Approximately 30-40% of colorectal cancer begins in the rectum, which is 
defined as the distal margin of the tumor within 15 cm of the anal verge [2, 3]. 
Given the vitality of the difficult anatomy of the rectum within the pelvis and surrounding 
visceral structures, accurate preoperative staging by suitable imaging modality is 
essential to determine the consequent treatment. 
Staging rectal cancer by a multidisciplinary team and accurate diagnostic imaging helps 
provide the best care for patients by offering treatment modalities, by guiding patients for 
either pre-operative chemo-radiotherapy or surgical management and assessment of 
prognosis of the tumor.  
The multidisciplinary team includes colorectal surgeons, gastroenterologists and both 
radiation and medical oncologists. 
Adequate surgical resection is considered the mainstay of treatment for rectal cancer; 
further, in the early stage of rectal cancer, the five-year survival rate is more than 90%, 
while for advanced-stage rectal cancer, the five-year survival rate is less than 10% [4].  
Endorectal ultrasound (ERUS) has become the most prevalent diagnostic imaging 
modality for the local staging of rectal cancer; it is safe and less expensive [5, 6].  
	   2	  
The muscularis propria of the rectum is a layer of muscle tissue considered the most 
important anatomic structure for physicians. It helps them decide whether the lesions are 
suitable for local excision if muscularis propria is not at the infiltrated stage (T1), or if 
extensive surgery is necessary if muscularis propria seems to be at the infiltrated stage 
(T2) or (T3). The accuracy and precision of muscularis propria involvement by the ERUS 
are superior compared to other existing imaging modalities [6]. 
Transanal local excision or endoscopic microsurgery is the modality of treatment for 
stage T1 or lower [7, 8], while a total mesorectal surgery would be used for stages T2 and 
T3. 
Early detection in curable stages and accurate diagnosis can influence the therapeutic 
strategy and improve outcome. There is a consensus regarding the role of ERUS in local 
staging rectal cancer and how commonly it is used due to lower costs and patient 
accessibility to the equipment.  
The focus of this review is to perform a systematic assessment that analyzes the accuracy 
and limits of the endorectal ultrasound (ERUS) method in early-stage CRC in comparison 
to the histopathology findings of the subsequent surgical specimen, and that highlights 
the impact of the ERUS value in staging CRC.  
Developing systematic reviews that are applicable for clinical practice stances a major 
challenge, and requires strong idea about the possibility and purpose of the review. 
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1.2-Description of the intervention: 
The endorectal ultrasound (ERUS) technique is the best diagnostic tool for the pre-
treatment staging of rectal cancer; it examines the thickness of the rectal wall, assesses 
the depth of tumor invasion and helps in distinguishing between tumors localized to the 
rectal wall and tumors with transmural invasion [9]. A combination of imaging 
modalities such as computed tomography (CT), magnetic resonance imaging (MRI) 
and/or endorectal ultrasound (ERUS) are used to accurately measure the extent of rectal 
cancer. Endorectal ultrasound (ERUS) is considered the first choice for diagnostic 
modality; in ERUS, a tiny ultrasound transducer is installed on the tip of the endoscope to 
allow the transducer to get closer to the body’s organs to achieve high-quality ultrasound 
images, thus providing enhanced details about the organs inside the body. ERUS probes 
are available in different lengths, diameters, and frequencies. The higher the ultrasound 
frequency, the better the resolution, with an accuracy range from 85-95% for assessing 
the depth of rectal cancer invasion, published in many articles [10, 11, 12, 13, 14, 15].  
It is the only method that has the capability to show images of the layers of the bowel 
wall, which can discriminate between T1 and T2 tumors [10]. ERUS indicated a better 
accuracy than other imaging modalities to assess the depth of invasion. The range for CT 
scans is between 65-75% and 75-85% for MRIs [16, 17, 18]. 
ERUS is a simple procedure usually done as an outpatient; most patients undergo ERUS 
simultaneously through the same colonoscopy session with conscious sedation. 
Before the procedures start, a digital rectal examination will be performed to describe the 
tumor size, location, and distance from the anal verge. The patient will be in a left lateral 
position and the trans-anal probe covered in a water-filled balloon to allow for 
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visualization of the rectum and perirectal area and avoid compression of the tumor by the 
ultrasound probe, which leads to overstating. This probe is inserted into the rectum above 
the level of the tumor, then slowly withdrawn until it reaches the tumor level for 
complete evaluation of the tumor and lymph node and to assess the degree of rectal 
invasion [19]. 
The higher frequency (2, 12.5, 15, 20, 25 and 30 MHz) ultrasound allows for better 
resolution of the rectal wall layers and inspection of stenotic lesions, while the lower 
ultrasound frequencies are used for assessment of lymph nodes and perirectal tissue 
invasion [20, 21]. Digital ultrasound images are saved on a computer file. 
The probe is inserted into the rectum above the level of the tumor, and then slowly 
withdrawn until it reaches the tumor level for complete evaluation of the tumor and 
lymph node and to assess the degree of rectal invasion [14]. Ultrasound can visualize the 
five layers of the rectum; usually they alternate between hyperechoic (white) and 
hypoechoic (dark) layers. Two are hypoechoic, three are hyperechoic and carcinomas are 
usually hypoechoic; the degree of penetration of the rectal wall layers suggests local or 
advanced-stage disease [22]. The first hyperechoic layer resembles a water-filled balloon; 
the mucosa represents the second hypoechoic layer while the third hyperechoic layer 
corresponds to submucosa. Muscularis propria, the fourth layer (hypoechoic) and the fifth 
layer (hyperechoic) relate to the interface between muscularis propria and perirectal fat 
[23, 24]. EUS is the only method that has the capability of imaging the layers of the 
bowel wall, which can discriminate between a lesion on the sub mucosa and muscularis 
propria (T1-T2 rectal tumors) [10].  
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1.3-How systematic review will contribute to our understanding of the 
problem addressed: 
Systematic reviews are used to review a clearly formulated question with careful 
consideration of a review’s methodological approach. It identifies all evidence and 
analyzes data from the studies that would decide which research could be included or 
excluded based on inclusionary eligibility criteria to answer a specific research question. 
[25,26]. In this thesis, the systematic review approach will be conducted to answer a 
certain question in relation to the advantage of ultrasound diagnostic imaging in early-
stage rectal cancer. 
The result of this thesis may improve the guidelines with respect to the added 
value of using an ultrasound in clinical practice for diagnosing early-stage rectal 
cancer and identifying further research needs by providing and synthesizing more 
reliable findings from the included studies about this specific research topic so as 
to aid in decision-making.  
In addition, systematic review can perform an assessment of the validity of the 
review’s outcomes, for example, evaluation of the risk of bias and confidence in 
cumulative estimates. 
The PRISMA-P was followed in this review, which consists of checklist items 
divided into three parts: administrative information, introduction, and methods 
[27]. 
This checklist was designed to improve the conduct of systematic reviews, 
provide readers with a complete acceptance of evidence from existing studies, and 
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help in the evaluation of the effects of interventions in early-stage rectal cancer. 
See Appendix. 
1.4-Gap of the evidence: 
Early and accurate diagnosis can influence the therapeutic strategy and improve the 
outcome. Agreement exists regarding the role of ERUS in the local staging of rectal 
cancer and how commonly it is used due to lower costs and patient accessibility to the 
equipment. However, some studies showed inferior results from the EUS due to the 
experience of effects of the results. 
A systematic review is necessary to highlight the value of the diagnostic test accuracy of 
ERUS imaging in staging preoperative rectal cancer	  (CRC) and to determine the efficacy 
of evaluating the depth of colorectal cancer invasion. 
In a review of the Cochrane database, Medline indicated two previous reviews performed 
in 2008-2009, which covered the diagnostic accuracy of EUS in the early staging of 
CRC. 
1.5-HTA in diagnostic test: 
Various details exist between diagnostic technologies evaluation and medical 
therapeutics. The most significant detail is that diagnostic test results influence outcomes 
but cannot determine health outcomes in patients. Tests performed on a person who has a 
symptom or sign of illness are usually termed diagnostic. Diagnostic tests are a critical 
component of health care; clinicians and patients usually have several questions 
regarding diagnostic tests, such as: What is the test used for? Does it improve the 
outcome? Is the test recommended in practice guidelines? How are the test results 
interpreted?  
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Imaging techniques allocate the generic features of all diagnostic tests; however, several 
issues are abnormal when imaging tests: 1-the test results are frequently 
multidimensional, 2-clear-cut points are rarely established, 3-images can reveal signs of 
different diseases, 4-imaging techniques may be associated with the risk of radiation-
induced side effects, leading to a clinical tradeoff between benefit and harm, 5-image 
quality increases with improved resolution and 6-many emerging imaging tests are 
expensive.  
Finally, an important feature of the evaluation of a diagnostic procedure is that different 
readers can assess images at different times, which allows us to analyze intra- and inter 
observer agreement. 
There are six levels of diagnostic efficacy assessment: (a) technology, (b) diagnostic 
accuracy, (c) diagnostic thinking, (d) therapeutic planning, (e) patient outcomes and (f) 
society. 
Level one is the domain of physicists and engineers who develop and refine an imaging 
technology before its clinical implementation and testing. 
Level two is sensitivity and specificity, positive and negative predictive values or 
receiver operating characteristic (ROC) curves. 
Level three, or “diagnostic thinking efficacy,” is used to measure the effect of diagnostic 
test results on the thinking of physicians. 
The likelihood ratio represents the ratio of the frequency of a certain test result in patients 
with a disease to its frequency in patients without the disease. The likelihood ratio can be 
used to judge the usefulness of a particular test in a given clinical situation [28]. 
Advocates of evidence-based medicine have also recommended the use of likelihood 
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ratios in the evaluation of diagnostic technologies [29]. 
Level four is known as “therapeutic planning efficacy. Level five, or “patient outcome 
efficacy,” can really be assessed only in a prospective RCT, in which only some of the 
patients undergo the test and patient outcomes in the two groups (test vs. no test) are 
compared. 
Level six, or “societal efficacy,” asks whether the societal benefit associated with the test 
is acceptable in relation to its cost [30]. 
Technology description of any diagnostic test is highly dependent on the population, 
disease and other features of the setting in which it are used. 
In the absence of clinical data, diagnostic tests are estimated based on test accuracy – the 
ability of the test to correctly determine the disease status of an individual. Test accuracy 
is not a measure of clinical effectiveness and improved accuracy does not necessarily 
result in improvement. 
Diagnostic tests are used to monitor therapeutic measures. Ideally, an evaluation should 
assess the clinical utility of a test. This evaluation was presented in two measures, namely 
sensitivity and specificity, to describe the characteristics of a diagnostic test. 
A positive test result might lead to the induction of therapy when it otherwise might not 
have been considered. A negative test might lead to the decision not to initiate therapy 
when it otherwise would have been given [31]. 
 
 
 
 
	   9	  
1.6-Measures of diagnostic accuracy: 
Sensitivity  
Specificity  
 Positive and negative predictive value  
 The area under a receiver operator characteristic (ROC) curve  
 Likelihood ratios of positive and negative test results  
Diagnostic odds ratios 
Why are we doing diagnostic test accuracy?  
Studies are easy to undertake; answers can be achieved quickly; required sample sizes are 
feasible and results do not depend much on human and health service factors.  
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Figure 1: The 2x2 contingency table 
 
 	   Reference standard	  
Positive	   Negative	  
Index test	   Positive	   TP	   FP	  
Negative	   FN	   TN	  
 
Sensitivity =	  
 
	  
The proportion of people with the target condition who have a positive test result.	  
How good is this test at identifying people with the condition?  
 
Specificity =	   	  
The proportion of people without the target condition who have a negative test result.	  
How good is this test at correctly excluding people without the condition?
	   	  	  
Chapter 2                                      
                                                Rectal cancer 
2.1-Epidemiology: 
The incidence of colorectal cancer is 15 times higher in adults older than 50 years; it is  
 40% higher in men than in women and the mortality rates are highest in African 
American men and women [32]. About 72% of cases arise in the colon and about 28% in 
the rectum. It is uncommon to have CRC before the age of 40, except if there is a 
predisposing condition. 
The incidence and mortality rate of CRC have been declining for the last several decades. 
This decrease in incidence has been influenced by the improvement of diagnostic 
techniques, screening programs, the removal of precancerous polyps and patient 
education [33-34]. 
 
2.2-Risk factors:  
Many factors increase the risk of CRC; about 75% of colorectal cancers are sporadic and 
the etiological factors include physical inactivity, high fat and high consumption of red 
meat such as beef, lamb and processed meats. People who are overweight have a greater 
chance of developing colorectal cancer, cigarette smoking consider as an important risk. 
There is a link between colorectal cancer and heavy alcohol consumption [35,36,37]. 
The remaining 25% of cases occur in people who have a family history of CRC or 
adenomatous polyps or a personal history of chronic inflammatory bowel disease. 
Other significant risk factors are genetic predispositions such as hereditary non-polyposis 
colorectal cancer (HNPCC), which is correlated with mutations in genes involved in the 
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repair pathway of DNA (MLH1 and MSH2) genes; responsible mutations in individuals 
with HNPCC can also cause Lynch syndrome [38]. 
Additionally, inflammatory bowel disease (IBD), which includes ulcerative colitis, 
Crohn’s disease increases an individual's overall risk of developing colorectal cancer  
[39], besides familial adenomatous polyposis (FAP), which is caused by changes 
(mutations) in the APC gene that a person receives from his or her parents.  
Families with a history of adenomatous polyps in one or more first-degree 
relatives are at increased risk [40]. People with FAP are at a higher risk for other 
cancers, such as cancer of the stomach and small intestines. 
People with a history of adenomatous polyps in one or more first-degree relatives are at 
an increased risk of developing rectal cancer [40]. 
 
2.3-Clinical presentation: 
• Bleeding from the rectum  
• Blood in the stool  
• Dark- or black-colored stools 
• Cramping  
• Discomfort or an urge to have a bowel movement  
• Constipation or diarrhea  
•  Other symptoms such as a change in bowel habits, weight loss, abdominal pain, 
and anemia [41,42]. 
The diagnosis is usually made by digital rectal examination to assess the rectal tone and 
detect penetration of the mass into the external and internal sphincters.  
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Some blood work (carcinoembryonic antigen measurement) is done, in addition to 
sigmoidoscopy and colonoscopy, double-contrast enema examination and histologic 
confirmation. 
 
2.4-Staging: 
The TNM staging system by the American Joint Committee (AJCC) is the recommended 
staging system for colorectal cancer [43]. 
Staging is the predictor of survival for patients with colorectal cancer [44]. 
The T refers to the extent of the primary tumors. The N refers to the involvement of 
regional lymph nodes and the lymphatic system. The M refers to metastatic disease. 
Tis carcinoma in situ does not have any metastatic potential. T1 tumors invade the 
submucosa; without evidence of invasion into the muscularis propria, T2 tumors invade, 
but do not go through, the muscularis propria. T3 tumors invade the muscularis propria 
and infiltrate the perirectal fat. T4 tumors invade surrounding organs and structures. 
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Table 1. Staging rectal cancer: 
Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: Intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades the muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures	  
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional nodal metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumor deposit(s) in the subserosa, mesentery, or non-peritonealized 
pericolic or perirectal tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes	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Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis	  confined	  to	  1	  organ	  or	  site	  (i.e., liver, lung, ovary, 
non-regional node) 
M1b Metastases in more than 1 organ/site or the peritoneum	  
 
AJCC stage	   TNM stage	  
Stage 0	   Tis N0 M0	  
Stage 1	   T1 N0 M0	  
Stage 1	   T2 N0 M0	  
Stage IIA	   T3 N0 M0	  
Stage IIB	   T4 N0 M0	  
Stage IIIA	   T1-2 N1 M0	  
Stage IIIB	   T3-4 N1 M0	  
Stage IIIC	   AnyT, N2, M0	  
Stage IV	   Any T, any N, 
M1	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T1: 
The tumor invades submucosa without invading the muscularis propria. 
Accurate diagnosis of a T1 rectal cancer is essential in determining treatment options, 
which include either local excision or oncologic resection [45-46]. 
Local excision by transanal excision or transanal endoscopic microsurgery is performed 
only in certain patients if the rectal tumor is less than 3 cm, less than 8 cm from the anal 
verge, well to moderately differentiated and absent of lymphovascular or perineural 
invasion. 
In the presence of lymphovascular invasion or poorly differentiated histology, T1 rectal 
cancer oncologic resection should still be endorsed [47]. 
T2: 
The tumor invades the muscularis propria. It has always been difficult to stage T2 
because the muscularis propria could appear thickened and irregular, which could be 
attributed to the presence of an inflammatory lymphocytic infiltration at the edge of the 
tumor. 
This may lead to an over-staging problem, 22-24. 
Local excision is not recommended in T2 due to a high local recurrence of more than 
20% [48-49]. 
 
 
 
 
 
	   17	  
 
2.5-Surgical options for rectal cancer treatment: 
In the early stages, rectal cancer surgery is the standard care for treatment, with the goal 
of optimizing oncologic control while reducing the effects of treatment on quality of life; 
therefore, different methods were recommended, including local excision and transanal 
endoscopic microsurgery (TEM). 
Local excision is used to treat stage T1N0 rectal cancers, with strict selection criteria 
including a freely mobile lesion less than 3 cm in size and less than 30% of the bowel 
circumference, histology being well-to-moderately differentiated and a lack of 
involvement of lymphovascular or perineural invasion and negative node. Local excision 
is associated with a higher recurrence rate (40%), especially if it is used in higher risk 
stage I rectal cancer (T2) lesions [50].  
The transanal endoscopic microsurgery (TEM) procedure was presented in 1984 as a 
minimally invasive procedure that served as an alternative to radical surgery and that 
provides better visualization of tumors and allows for the excision of lesions located in 
the rectum by endoscopic view of the rectum with decreased morbidity and mortality. 
The procedure is technically challenging due to the narrow operating field; the patient 
undergoes general anesthesia and a bowel preparation, then is placed supine or prone on 
the operating table to keep the lesion close to the 6 o’clock position. The TEM technique 
includes a laparoscopic camera, an operating proctoscope and modified laparoscopic 
instruments. 
After a dilating digital exam, a proctoscope is inserted through the anus with a length of 
20 cm and a 4-cm diameter. After insertion of the proctoscope, the lesion is identified and 
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the proctoscope is fixed to the operating table. The proctoscope has a port for high-flow 
carbon dioxide to maintain dilatation of the rectum [51]. 
The faceplate of the proctoscope has four ports for insertion of instruments, including a 
camera and three modified laparoscopic instruments to ease the full-thickness excision of 
rectal lesions; tumor excision is performed by monopolar hook cautery [51]. 
Several retrospective and prospective studies reported that TEM is highly successful, 
with the advantage of fast recovery [52], the absence of scars, a rapid return to regular 
activities [53], a decreased need for colostomies, a short hospital stay with less operating 
time, only brief use of analgesia, a decreased rate of complication of 2-12% [54,55] and 
recurrence rates of 0–19% [56,57]. 
TEM is an oncological procedure that is safe for early-stage rectal carcinomas and that 
has achieved low local recurrence and high survival rates. Complications after TEM are 
considerably rare, mainly urinary difficulty. 
In case of positive resection margin or unfavorable histology, total mesorectal excision 
(TME) surgery will be performed [58]. 
If the pathology revealed a T2/T3 rectal cancer, patients’ cases will be presented at tumor 
board meetings for offering additional radical surgery, including low anterior resection 
(LAR) or abdominoperineal resection (APR). 
LAR involves mobilization of the rectum, sigmoid colon, by performing mobilization of 
the rectum; a technique called total mesorectal excision (TME) is required. 
TME is the therapeutic gold standard in patients as a part of low anterior resection for 
middle and lower third rectal cancers; it is a procedure defined as the excision of the 
rectum with the surrounding mesorectum at the level of the pelvic floor. 
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The patient is positioned in a lithotomy position. A Foley catheter is inserted and the 
rectum is irrigated with both saline and iodine. Ureteral stents are placed if indicated and 
a temporary colostomy or ileostomy is performed in case of LAR in addition to intensive 
postoperative monitoring. Most of the time, TME is performed laparoscopically in bloc 
resection of the rectal cancer with a complete pararectal lymph node dissection in 
addition to the resection of radial and circumferential margins, not breeching the fascia 
propria of the rectum [59]. Postoperative complications of TME include an increased risk 
of anastomotic bleeding, urinary leakage, urgency and the feeling of incomplete bladder 
emptying, while the lower anterior reaction side effects include sexual and urinary 
dysfunction, dehiscence, intestinal obstruction, anastomotic site stenosis, stoma problems 
and fistula [60]. 
An abdominal perineal resection (APR) is still done in selected patients with low-lying 
rectal adenocarcinomas or poor sphincter function.  
APR includes the resection of the sigmoid colon, rectum, and anal sphincter using both 
anterior abdominal and perineal incisions and resulting in a permanent colostomy. 
Patients who undergo APR must have one of these criteria: progressive rectal cancer, 
failure to achieve a negative distal margin by a sphincter-sparing procedure or local 
recurrent [61]. 
The importance of accurate staging of rectal cancer is essential for the clinician in helping 
patients select appropriate management, to identify patients who can undergo sphincter-
preserving surgery or new adjuvant treatment and to foresee prognosis. 
Many imaging modalities are utilized for staging rectal cancer, but the precision of EUS 
in the literature has been varied for T1 and T2 diagnosis; therefore, we conducted a 
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systematic review to summarize the accuracy of EUS and to predict the impact of EUS in 
the diagnostic workup by under diagnosing T1 or not recognizing it, and then performed 
a decision analysis to evaluate the added utility of EUS. 
 
2.6-Diagnostic imaging: 
Several imaging techniques’ modalities are used in the pre-operative staging of colorectal 
cancers, such as computed tomography (CT), magnetic resonance imaging (MRI), 
endorectal ultrasound (ERUS) and positron emission tomography (PET) with and without 
CT fusion. 
Each modality has its own benefits and drawbacks; the benefits should be weighed 
against the drawbacks of using the modality. An important element in choosing an 
imaging modality for staging is the availability of that imaging modality. 
MRI and ERUS are considered the two standard imaging techniques used for the primary 
staging of rectal cancer [10] 
A computed tomography (CT) scan is considered in the staging of rectal cancer for the 
detection of metastatic disease spread to the liver and/or lungs; the accuracy of CT (T-
stage) improves in more locally advanced tumors than in early staging [62]. 
A CT scan is not useful in evaluating the layers of the rectal wall due to inherent low-
contrast resolution presented by CT imaging techniques. It can precisely detect lymph 
nodes staging in a range from 54 to 70% [19]. 
High-resolution magnetic resonance imaging (MRI) is considered an important 
component of rectal cancer staging. MRI is used to measure the extent of a tumor in the 
adjacent mesorectum and tumor proximity to the mesorectal fascia (MRF) to determine 
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the risk of local recurrence and identify nodal involvement [20]. 
If MRF was involved or proximal to the tumor, this would expand the risk of 
compromised radial, the circumferential resection margin CRM after radical surgery [21]. 
MRI fails to differentiate between T1 and T2 cancers because the submucosal layer is 
usually not visualized on MRI [63]; also, MRI cannot differentiate between T2 and T3 
cancers because of the desmoplastic reaction seen near tumors [64,65]. A high-resolution 
MRI image appears to be superior to EUS for locally advanced disease and for the 
detection of lymph node metastases.  
Nodal staging by MRI ranges between 39 and 95% [66,67,68,69]; it allows for 
visualization of nodes as small as 2 mm in the entire mesorectal part, as well as outside 
the mesorectum [67].  
PET/CT scan with radioactive glucose is useful in displaying whether the cancer has 
spread to lymph nodes or nearby structures, or in the case of obstructing colorectal 
cancers; in addition, it will aid in the detection of a suspected recurrence of CRC or 
tumor response to therapy [69,70].  
Few studies have suggested that preoperative PET combined with CT scan improves the 
staging of rectal cancer [71] and plays a role in changing preoperative management in 
about 17% of patients [72]. However, PET/CT is not used routinely for the staging of 
primary rectal cancer, as no specific evidence supports the routine clinical use of 
PET/CT.  
 
	   	  	  
CHAPTER 3:                  
                                              Research Objective 
3.1-Aim of the study review: 
This study aims to perform a systematic review that analyzes studies to evaluate the 
diagnostic imaging accuracy of ERUS (endorectal ultrasound) in adult patients with 
local-stage rectal cancer as well as to summarize the diagnostic test accuracy (e.g., 
sensitivity, specificity) in comparison to the histopathology findings of the subsequent 
surgical specimen, thus highlighting the impact of EUS value in staging CRC. This study 
will also provide future practice recommendation. 
 
3.2-Review question(s): 
• What is the diagnostic accuracy of imaging techniques (ERUS)? (Measuring 
sensitivity and specificity) 
• What is the impact of imaging techniques on the clinical outcome? 
 
3.3-Primary objective:  
The primary objective of this study is to systematically review the currently published 
articles that evaluate the diagnostic test accuracy of using endorectal ultrasound for the 
staging of primary rectal cancer. The review compares ERUS and histopathological 
findings for staging early rectal cancer patients. 
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3.4-Specific objectives: 
To extract information about imaging diagnostic tests for the investigation of rectal 
cancer. 
To identify all studies in the existing literature related to the diagnostic accuracy of 
ERUS used to detect early stages of rectal cancer. 
To extract data on sensitivity and specificity for (T1, T2) rectal cancer. 
To synthesize and compare extracted data to pathology staging.  
	  	  	  
CHAPTER 4:                                 
                                                   Methodology 
4.1-Methods: 
We will perform a literature search that inspects the studies identified and choose those 
that meet the eligibility criteria. The description of methods in this chapter will match the 
diagnostic test accuracy methods at Cochrane Collaboration [73]. Next, the data will be 
extracted from the selected studies for an evaluation of their methodological quality. 
In this chapter, we follow the Preferred Reporting Items for Systematic Review Protocols 
(PRISMA-P) recommendations [74] Appendix C. 
 
4.2-PICO frameworks 
Participants/Presentation  
Inclusion: All adult patients ≥18 years, undergoing pre-operative ERUS staging and 
diagnosed with primary rectal cancer stage 1 (T1/T2) will be eligible for inclusion. 
Exclusion: People under 18 years, studies focusing on patients with advanced-stage rectal 
cancer, recurrent cancer, or metastasis and patients who received neoadjuvant treatment. 
Studies that did not meet all the inclusion criteria, Case reports, crossover studies and 
abstract material were not included in determining the accuracy of the study. Studies 
performing EUS after treatment, restaging imaging for follow-up or investigating local 
recurrence rates or responses to treatment were all excluded. So were studies not 
reporting an endoscopic ultrasound as a diagnostic measure, studies in which the 
restaging findings were not compared with pathological results, duplicate studies and 
other types of cancer. 
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Index test 
The index test is endorectal ultrasound (ERUS)/endoscopic ultrasound (EUS). 
All studies that evaluated the accuracy of ERUS as diagnostic imaging in primary 
colorectal cancer were included. 
All studies involving humans were included. Studies performing this investigation after 
treatment or investigating recurrence rates or responses to treatment were excluded. 
Patients who were staged preoperatively by other imaging modality (MRI or CT) were 
excluded. 
 
Comparator (reference standards) 
The reference test is the “gold standard” test to which physicians use the results from the 
index test (ERUS) to reach a stage compared to the one founded by the reference 
standard. In this review, we included studies that used the histopathology of surgically 
resected specimens as a reference standard for the pretreatment staging of CRC. 
We pursued comparative studies of ERUS test accuracy that evaluated the (ERUS) index 
test versus histopathology following either surgery or biopsy in staging early rectal 
cancer.  
These comparisons will advise how many patients were staged correctly and allow us to 
calculate the test performance of sensitivity, specificity, and accuracy.  
 
 
 
 
	   26	  
Outcome(s): 
Primary outcome 
• Diagnostic accuracy (sensitivity, specificity) of tumor staging by ERUS 
• Test performance (understaging, overstaging) against a reference standard test 
(pathology examination) 
• Changes in therapeutic management  
• Impact of survival 
Secondary outcomes 
None 
 
Time frame studies: 
A well-defined period of time will be considered for research, starting form  
2009- September 2016. 
 
4.3. Criteria for study inclusion and exclusion: 
Condition or domain being studied: 
The target conditions were colorectal cancer patients. 
Study types include:  
Diagnostic studies were included with any study design that evaluated test accuracy of 
EURS diagnosis, and compared with histopathology.  
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Findings: 
Diagnostic case-control studies were excluded because clinically relevant estimates of 
specificity and sensitivity can be derived only from the clinical population and not 
healthy controls. 
Exclusion:  
Case reports because they lack sufficient diagnostic test accuracy data. 
Case-control studies because they are prone to bias and estimates of specificity and 
sensitivity, which can be derived only from the clinical population and not healthy 
controls [75]. 
Conference abstracts because they do not include adequate details about experimental 
methods to permit an evaluation of study design and conduct.  
Cross-over studies. 
Setting: 
Studies from the clinic or hospital were included. 
Full-length articles: 
The articles had to be published as full-length, peer-reviewed studies. 
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Prospective study: 
A prospective study collects data in the process, assesses outcomes, and is a good choice 
for rare exposure. The study usually involves taking a cohort of subjects and monitoring 
them over an extended period of time. Prospective studies usually have fewer potential 
sources of bias and confusion than do retrospective studies. The weaknesses of 
prospective studies include loss of follow up and difficulty selecting and maintaining a 
non-exposed group. 
Retrospective study: 
A retrospective study is one that collects data from the past; it looks backwards and 
examines exposures to investigate risk or protection factors in relation to an outcome, 
making this type of study appropriate for studying multiple outcomes. Most sources of 
error due to confusion and bias are more common in retrospective studies than in 
prospective studies, but timeframes for completion are usually short in retrospective 
studies. With respect to weaknesses, retrospective studies cannot demonstrate 
temporality; an investigator has no control over exposure and requires a large sample for 
rare exposure. 
In the assessment of the diagnostic test, both retrospective and prospective studies are 
used to assess and compare accuracy. A retrospective study is usually recruited based on 
whether patients have the disease. In contrast, for a prospective study patients are 
selected based on their symptoms [75]. 
Observational study designs are admissible in our study; they include retrospective and 
prospective cohorts. Diagnostic study designs division of observational studies which 
evaluate the accuracy of diagnostic procedures and tests as compared to other diagnostic 
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measures, including diagnostic accuracy designs and diagnostic cohort designs [76]. 
The crossover study design was excluded from our study because a crossover design is a 
repeated measurements design in which patients receive different treatments during 
different time periods; it is a controlled trial in which each participant receives both 
therapies in a random order and is relevant only if the outcome, such as symptoms, is 
reversible with time. 
The main disadvantage of the crossover study is the carryover effects, defined as the 
effects of the treatment from the previous time period on the current time period’s 
response; these effects cannot be estimated separately [77]. 
 
4.4-Search strategy: 
Early scoping research: 
An initial systematic review of the literature was performed for articles published in the 
last 16 years about the diagnostic accuracy of ERUS in the staging of CRC by searching 
the databases: 
1-PubMed 
2-EMBASE 
3-Ovid 
4-Cochrane Library, which includes Cochrane Reviews, DARE and the Central Register 
of Controlled Clinical Trials 
All articles were in the English language. 
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Search strategy: 
In consultation with a librarian specialist in electronic bibliographic databases, 
information was identified for scoping the research. The guidelines for building a search 
strategy in each database were consulted. The search strategy used text words to identify 
articles discussing the accuracy of endorectal ultrasound in staging patients diagnosed 
with early rectal cancer. 
The following electronic databases were used: MEDLIN (Ovid, PubMed), EMBASE and 
Cochrane Database; with modifications to search terms as necessary (see appendix A,B) 
A limitation with respect to the publication year (2009 to 2016) was applied.  
The search strategy used text words and relevant indexing to identify articles discussing 
the diagnostic accuracy of endorectal sonography for early detection of rectal. Results 
were limited to articles published in English between 2009 and 2016 in a peer-reviewed 
journal, terms relating to the intervention, text in the English language and text applying 
only to humans. Conference abstracts, comments, case reports, editorials, and letters were 
excluded. 
Relevant studies of the diagnostic accuracy of ERUS in the staging of rectal cancer were 
identified. 
 
4.5-The key search term: 
To guarantee an efficient search, medical subject headings (Mesh) words, were used to 
define relevant articles for our study. For each database, keywords and index terms were 
used to identify other index terms to determine the relevance of each term.  
Subsequently, while categorizing the keywords, we added “OR” and “And” to make our 
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search more precise.  
The full MEDLINE strategy was applied to all databases, with modifications to search 
terms as necessary. 
The MEDLINE database was searched using these keywords: (a) 
“rectal neoplasm” (medical subject heading, or Mesh), (b) “EUS” (Mesh) or 
“ultrasonography” (Mesh) and (c) “specificity”, “sensitivity” or “accuracy”. 
The EMBASE, Cochrane databases were also checked for significant articles by applying 
(a) “rectal cancer” and (b) “ultrasonography”, “accuracy” or “histopathology”.  
We used terms such as “sensitivity and specificity” or “accuracy”, called methodological 
search filters; the search terms used are described in detail in the Appendix A-B.  
 
4.6-Study selection: 
Initially, one reviewer screened titles and abstracts for relevant studies. At this stage, 
studies were excluded if the condition was not early rectal cancer, if the study performed 
on patients received neoadjuvant treatment, if the study included recurrent cancer or 
metastases, or if the study did not use ERUS. Full texts of identified articles were then 
obtained and assessed for study eligibility using the full set of inclusion and exclusion 
criteria. The study selection process was illustrated using a PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. See 
Appendix E. 
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4.7-Search methods for identification of studies: 
Systematic electronic searches were customized to each of the following databases: 
MEDLINE via Ovid SP (2009 to September 2016; Appendix A.1) 
Medline via PUBMED (2009 to September 2016; Appendix A.2) 
EMBASE via Ovid SP (2009 to September 2016; Appendix A.3) 
The Cochrane Library (2009 to September 2016; Appendix A.4) 
In addition, reference lists for all included papers were searched for relevant studies. 
All results were collected and duplicate studies removed and exported to EndNote 
version 7.0. 
The selection of qualified studies was performed in a stepwise approach (titles and 
abstracts, then full texts). 
Research Ethics Board review was not required for this systematic review. 
Studies eligible for our systematic reviews were required to compare ERUS assessment 
of T stage with histopathology T stage for early rectal cancer. 
 
4.8-Data source:  
Studies were classified by searching a range of electronic databases and reference lists of 
relevant studies. 
We looked in the systematic review at the diagnostic accuracy of ERUS and compared it 
with the pathology result after the surgery. 
ERUS studies were selected based on surgical histology. Standard criteria were used to 
determine the T stage:  
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T1: Hypoechoic mass in the lamina propria or submucosa, without evidence of invasion 
into the muscularis propria. 
T2: Hypoechoic mass invading the muscularis propria. 
 
Definitions: 
Accuracy: the percentage of patients in whom the diagnostic imaging ERUS for staging 
rectal cancer matched the pathological stage. 
Under-staging: the percentage of patients in whom the ERUS stage was less than the 
pathological stage. 
Over-staging: the percentage of patients in whom the ERUS stage was greater than the 
pathological stage. 
 
4.9-Data extraction: 
Data was collected according to the PICO framework, as explained above. One reviewer 
extracted data using the search strategy to identify studies that potentially met the 
inclusion criteria outlined above. This data was then verified by a second reviewer; both 
these reviewers, worked independently. All studies that met inclusion criteria were 
selected for full-text review. Relevant findings were summarized and presented in an 
evidence table. 
Data extraction will include the following variables: 
Study characteristics 
      Title  
First author 
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Year of publication 
Study design  
Confirmatory procedure 
Population characteristics: inclusion/exclusion criteria for individual studies 
Setting 
Intervention test 
       Outcome measures  
2x2 table for diagnostic studies presenting the sensitivity and specificity of T1-T2 
rectal cancer 
 
4.10-Assessment of methodological quality (risk of bias): 
Each full paper was assessed for risk of bias by one reviewer and proven for accuracy 
with respect to all the assessed studies by another.  
This checklist is a modified version of the quality assessment of the diagnostic accuracy 
studies’ (QUADAS-2) assessment tool [78, 79], which will be used to assess the quality 
of the included diagnostic accuracy studies. 
QUADAS-2 consists of 4 key domains: 
These domains include patient selection, index test, reference standard, and flow of 
patients through the study and timing of the index test(s) and a reference standard to 
evaluate each article. The items were rated as yes, no or unclear. 
Each domain was assessed in terms of risk of bias; each of these domains also 
summarizes the review question, tailors the tool, produces review-specific guidance, 
constructs a flow diagram for the primary study and judges risk of bias and concern 
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regarding applicability [78]. 
The results of the quality assessment will be presented later to provide an evaluation of 
the quality of the selected papers.  
For the systematic reviews, methodological quality will be assessed using the AMSTAR 
tool [80],	   it’s an 11-item questionnaire that can be used to assess the methodological 
quality of systematic reviews by assessing the presence of: 
An a priori design; duplicate study selection and data extraction; a complete literature 
search; and the use of status of publication as an inclusion criteria; a list of 
included/excluded studies; characteristics of included studies; documented assessment of 
the scientific quality of included studies; appropriate use of the scientific quality in 
forming conclusions; the appropriate use of methods to combine findings of studies; 
assessment of the likelihood of publication bias; and documentation of conflict of 
interest. 
 
4.11-Strategy for data synthesis: 
Developing a philosophy of how, why and for whom the intervention works, we will 
create an initial synthesis of findings of included studies and explore the relationships 
within and between studies. Results of the evaluation of the accuracy of ERUS will be 
analyzed according to the diagnostic measures of sensitivities and specificities calculated 
for each study. We will produce the 2 X 2 contingency table for each study, so as to be 
able to determine the pooled estimates’ of sensitivity and specificity. 
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4.12-Graphic representation  
Results of diagnostic test accuracy systematic reviews can be represented as Forrest plots 
graph, one for sensitivity, and the other for specificity for each of the selected primary 
studies. 
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Table 2. Inclusion and exclusion criteria of selected papers 
	   Inclusion	  criteria	   Exclusion	  criteria	  
Population	   Adult patients with early 
rectal cancer	   -Children with rectal cancer 
-Adult patients with 
recurrent rectal cancer, 
metastasis or another 
type of cancer 
-Neoadjuvant/adjuvant 
therapy	  
Intervention	   Endoscopic ultrasound 
(EUS)	   	  
Comparator	   Endoscopic ultrasound 
with pathological staging	   No endoscopic ultrasound, no 
histopathology	  
Outcomes	   -Diagnostic accuracy 
-Survival 
- Changes in therapeutic 
management  	  
	  
Study	  design	   - Diagnostic studies with 
any study design.	   -Crossover -Case report 	  
Publication	  type	   -Original research 
manuscripts published in 
a peer-reviewed journal	   -Conference abstract -Abstract	  
Language	   All studies published in 
the English language	   Languages other than English	  
 
	  	  	  
Chapter 5:                                       
                                                         Result 
5.1-Result analysis: 
Two systematic reviews published 2008-2009 were identified [81-82]; a second search 
looking for other articles was then conducted using the same databases from 2009 to 
September 2016. The terms used for search were endoscopic ultrasound, EUS, rectal 
cancer, histopathology, and staging.  
Our search strategy identified 323 relevant articles of which 173 were excluded as titles 
articles and 118 as abstracts. Thirty-two studies were satisfied the eligibility criteria and 
retrieved for full-texts reviewed. After full-text review, 22 articles were excluded for 
various reasons. Thus, 10 articles published in peer reviews Journal as full text and met 
the inclusion criteria’s were included in this systematic review [Table 3]. Details of the 
selected papers are outlined in APPENDIX E in accordance with PRISMA guidelines for 
reporting of systematic reviews [93] figure 2. 
All patients in the 10 studies were assessed clinically and then underwent pre-operative 
ERUS examination, then they compared the result to asses the staging accuracy with the  
histopathology reports, which were  obtained for all patients. The results of each included 
study and the author’s conclusion were described in [Table 4]. The methodological 
quality (QUADAS-2) presents the percentage of included studies for which the item was 
rated “low,” “high” or “unclear,” for each quality assessment domain. (QUADAS-2) for 
each article are described in APPENDEX F. 
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Table 3. Characteristics of studies included in this analysis 
	   Year First 
author 
Study design 
& 
confirmatory 
procedure 
Intervention 
& setting 
Population 
characteristics 
Outcome 
measure 
1	   2011 
[83] 
Gloria 
Fernande
z 
Esparrac
h 
Prospective 
Cohort 
Surgery 
EUS and 
MRI 
Tertiary 
Center 
Mean age = 68 
Gender = 54 males, 
36 females 
Overstage  
Understage  
Sensitivity  
Specificity  
 
2	   2010 
[84] 
Jimmy 
C.M. Li 
Prospective  
Cohort 
Surgery 
ERUS 
Hospital 
Mean age = 67 
Gender = 36 males, 
31 females 
Overstage  
Understage  
Sensitivity  
Specificity  
3	   2011 
[85] 
Shiyong 
Lin 
Retrospective 
Surgery 
ERUS 
Hospital 
Mean age = 59 
(23-83) 
Overstage  
Understage  
Sensitivity  
Specificity 
	  4	    2014 
[86] 
 
D.Mond
el 
 
Prospective  
Surgery 
 
ERUS 
Hospital 
 
Mean age = 66 
Gender = 30 males, 
23 females 
Overstage  
Understage  
Sensitivity  
Specificity  
5	   2014 
[87] 
Rikesh 
Kumar 
Retrospective 
Analysis 
ERUS 
Tertiary 
Mean age = 58 
52 patients 
Overstage  
Understage  
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Patel Surgery Colorectal 
Center 
Sensitivity  
Specificity  
6	   2011 
[88] 
Davide 
Ravizza 
Retrospective 
Observational 
Study 
Surgery 
ERUS 
Division of 
Endoscopy 
Clinic 
Mean age = 63 
Gender = 56 males, 
36 females 
Sensitivity  
Specificity  
7	   2014 
[89] 
Alessand
ra Surace 
Retrospective 
Surgery 
ERUS 
Hospital 
Mean age =63 Sensitivity  
Specificity  
Overstage 
Understage  
8	   2010 
[90] 
Belk›s 
ÜNSAL
1 
Retrospective 
Study 
Surgery 
ERUS 
Hospital 
Mean age = 63 
Gender = 22 males, 
9 females 
   
Sensitivity 
Specificity  
 
9	   2012 
[91] 
J. Yimei Prospective 
Study 
Surgery 
ERUS and 
MRI 
Hospital 
Mean age = 62 
Gender = 77 males, 
52 females 
Sensitivity  
Specificity  
Overstage  
Understage  
10	   2009 [92] Luigi Zorcolo Retrospective Analysis 
Surgery 
ERUS 
Hospital 
Mean age = 66 
Gender = 46 males, 
35 females 
Overstage 
Understage 
Sensitivity  
Specificity  
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Table 4: The results of each included study and the author’s conclusion. 
 Year First	  
author 
Follow	  
up 
Result Conclusion	   
1 2011 
[83] 
Gloria 
Fernandez 
Esparrach 
2 years No significant differences 
between EUS and MRI in terms 
of sensitivity, specificity, positive 
and negative predictive value, 
and accuracy in T staging of rectal 
tumors 
EUS is good 
techniques for T 
and N staging of 
rectal cancer.  
2 2010 
[84] 
Jimmy 
C.M Li 
2 years The overall accuracy rates of uT   
and uN staging were 86 and 66%. 
High accuracy rate for uT staging. 
 
ERUS was 
accurate in 
preoperative 
staging 
of rectal cancer. 
3 2011 
[85] 
Shiyong 
Lin 
6 years The overall accuracy 
of ERUS T staging was 86.5%. 
When counted separately, 
the accuracy rates were 86.7% for 
sonographic 
stage T1, 94.0% for T2, 86.2% 
Endoscopic 
sonography is safe 
and effective for 
preoperative 
staging of 
rectal cancer and 
should be a routine 
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examination before 
surgery 
4 2014 
[86] 
D.Mondel 2 years Our study showed that in our 
institution, ERUS staging of 
early rectal tumours correlated 
with histopathological 
staging in 90 % of patients  
ERUS has a high 
accuracy in 
predicting the 
Tstage of early 
rectal cancers. 
 
5 2014 
[87] 
Rikesh 
Kumar 
Patel 
25 
months 
ERUS. T-staging was 
accurate in 73.1% with 
identification of  T1 lesions 
having a sensitivity of 70.8% and 
a specificity 100 % 
ERUS has 100% 
specificity in 
determining that a 
lesion is limited to 
the mucosa or 
submucosa, useful  
in determining 
suitability for local 
excision.  
 
6 2011 
[88] 
Davide 
Ravizza 
9 years The sensitivity, specificity, overall 
accuracy rate, PPV , and NPV of 
ERUS for pT0–1 were 86%, 
95.6%, 91.3%, 94.9% and 88.7%. 
ERUS has proved 
to be a reliable tool 
to identify rectal 
neoplasia suitable 
for local treatment 
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7 2014 
[89] 
Alessandra 
Surace 
4 years Specificity for T1 88.2% . 
Sensitivity and specificity for pT2 
stage are respectively 83% and 
91%.  
 
ERU represents 
very important 
radiological 
staging methods to 
evaluate T1 and T2 
rectal cancer 
8 2010 
[90] 
Belk›s 
ÜNSAL1 
1 year Endoscopic rectal 
ultrasonography had 80.6% 
accuracy, 93.4% sensitivity, and 
96.5% specificity in T stage. 
ERUS is an 
effective and 
reliable method in 
the detection of the  
(T staging) 
9 2012 
[91] 
J. YIMEI 1 year EUS had higher sensitivity in T1  
and specificity in T2  
 than MRI.  
Reference values for surgery  
EUS was. 76. 7%, The T 
Accuracy of ERUS was 83 %. 
 
ERUS is good for 
early-stage patients  
Combined TN 
staging 
 
10 2009 
[92] 
Luigi 
Zorcolo 
12 years ERUS enabled distinction 
between early and advanced rectal 
lesion with 96% 
sensitivity and 85% specificity, 
giving accuracy of 94% 
ERUS is useful to  
predict depth of 
mural invasion in 
early rectal 
cancer. 
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Results for the accuracy of ERUS analyzed and presented in a table according to the 
diagnostic measures of sensitivities and specificities that were calculated for each study 
[Table 6], then, we performed a Forrest plot (random-effects model) for sensitivity and 
specificity for each of the selected primary studies. These measures provide a clear 
indication of the diagnostic value of a test. 
 
Table 6: Diagnostic accuracy of EUS for T staging 
T1	  
 
 
Sensitivity Specificity 
Glòria Fernández 89% 96% 
Jimmy C. M 50% 50% 
Shiyong Lin 86% 87% 
D.Mondel 90% 89% 
Rikesh Kumar Patel, 71% 100% 
Davide Ravizza 86% 95% 
Alessandra Surace 77% 88% 
Belk›s ÜNSAL 100% 96% 
J. YIMEI 87% 97% 
Luigi Zorcolo 96% 94% 
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T2 	  	   Sensitivity	   Specificity	  
Glòria Fernández 50%	   83%	  
Jimmy C. M 70%	   100%	  
Shiyong Lin 95%	   78%	  
D.Mondel 90%	   75%	  
Rikesh Kumar Patel 76%	   100%	  
Davide Ravizza 87.5%	   95.9%	  
Alessandra Surace 83%	   90%	  
Belk›s ÜNSAL 72%	   100%	  
J. YIMEI 77%	   97%	  
Luigi Zorcolo 81	   85%	  
 
In these diagnostic test accuracy reviews, two Forrest plots are presented side by side: 
one for sensitivity and the other for specificity. These graphs thus show 95% of 
confidence intervals for each individual selected primary study. [Figures 3 and 4]. 
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Figure 3: T1 Forrest plot  
 
 
Figure 4: T2 Forrest plot  
 
 
The result of the accuracy of EUS for T1 rectal cancer, showed that the pooled sensitivity 
was 0.81 (95% CI 0.72– 0.8 ) and the pooled specificity was 0.89 (95% CI 0.81–0.94).  
However for T2 disease the pooled sensitivity was 0.78 (95% CI 0. 69–0.86) and the 
pooled specificity was 0.90 (95% CI 0.82–0.95).  
 
 
	   48	  
The accuracy of EUS with Confidence interval to T-Stage Rectal cancer from the 
systematic review and a meta-analysis by Puli et al [81] between 1986 and 2008 showed 
the pooled sensitivity and specificity of EUS for T1 88% (95% CI 85.–90.0%) and  
98.3% (95% CI 98-99%), and for T2 stage cancer, EUS had a pooled sensitivity of 80%  
(95% CI 78–83%) and specificity of  96% (95% CI 95–96%).  
The p value for all the pooled accuracy assessments was > 0.10. 	  Their conclusion was over the past two years, the sensitivity, and specificity of EUS to 
early stage rectal cancers has continued to be elevated, therefore EUS believed to be the 
most accurate investigative choice in staging early rectal cancer. 
The second met analysis and systematic reviews by Puli et al [82] had 11 studies that met 
the inclusion criteria and also printed in peer-review journals as full articles. They looked 
mainly on T0 staging rectal cancer. 
The Pooled sensitivity of EUS was 97.3% (95% CI: 93.7–99.1) and a pooled specificity 
of 96.3% (95% CI: 95.3–97.2). All the pooled are calculated by the fixed-effect model. 
We did not use the second systematic reviews [82] because it’s only looked at T0 rectal 
cancer. 
Next we added the pooled sensitivities, specificities, and the 95% confidence intervals for 
the articles included in the systematic reviews to the pooled analysis of sensitivity and 
specificity from the met analysis study [81] and we present the combined data in a 
Forrest plot figure [figures 5-6]. 
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Figure 5: Forrest plot showing sensitivity and specificity for T1 of our 
Systematic review combined with the meta-analysis study: 
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Figure 6: Forrest plot showing sensitivity and specificity for T2 of our 
Systematic review combined with the meta-analysis study: 
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Table 7: Sensitivity analysis including rectal cancer, results from 10-
pooled studies 
	   T1 T2 
Sensitivity 81% 78% 
CI  72–88  69-86 
Specificity  89% 90% 
CI 81-94  82-95 
 
 
Table 8: Pooled analysis from Pauli [81] systematic review for T-stage  
	   T1 T2 
Sensitivity 88% 80% 
CI  85-90  78-83 
Specificity  98% 96% 
CI 78-83%  95-96% 
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Table 9: The accuracy of EUS with Confidence interval from the 
combined analysis 
	   T1 T2 
Sensitivity 84% 83% 
CI  75–91.%  74-90% 
Specificity  93% 93% 
CI 86 –97%  86-97% 
 
5.2-Methodological quality  
This section includes a narrative summary of the overall methodological quality of the 
included studies, which will be presented in a table showing the results of the critical 
appraisal, which shows individual Y/N scores per study. The overall study quality that 
found in articles was moderate to good quality. 
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Table 5: Critical appraisal results for included studies using the JBI 
critical appraisal checklist 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
Author Gloria 
Fernande
z 
Esparrac
h 
Jimmy 
C.M. 
Li 
Shiyong 
Lin 
D. 
Mond
el 
Rikesh 
Kumar 
Patel 
Davide 
Ravizz
a 
Alessan
dra 
Surace 
Belk›s 
ÜNSA
L1 
J.  
Yimei 
Luigi 
Zorcolo 
Y/N/U Y Y Y Y Y Y Y Y Y Y 
Y - Yes, N - No, U – Unclear 
 
The methodological quality for the systematic reviews was assessed using the AMSTAR 
tool Appendix G, regarding (How Good is Endoscopic Ultrasound in Differentiating 
Various T Stages of Rectal Cancer? Meta-Analysis and Systematic Review) article [81] 
the AMSTAR score was 9/11, while for the other article (Can Endoscopic Ultrasound 
Predict Early Rectal Cancers That Can Be Resected Endoscopically? A Meta-Analysis 
and Systematic Review) [82] the AMSTAR score was 8/11.
	  	  	  
Chapter 6:                                          
                                                   Discussion 
6.1-Main findings  
Determining the management of rectal cancer and its early detection during curable 
stages improves the prognosis for any malignant neoplasia and predicts the chances of 
survival. 
The five-year survival rate for patients with stage I rectal cancer is 87%, and for stage IIA  
it is about 80%. For stage IIB cancer the five-year survival rate is about 49%, for stage 
IIIA rectal cancers it is about 84%, for stage IIIB cancers it is about 71%, and for stage 
IIIC cancers it is about 58%. 
Several choices exist for staging primary rectal cancer. Nevertheless, endorectal 
ultrasonography (ERUS) remains the most attractive modality. In this systematic review 
we look at the diagnostic accuracy of the ERUS imaging techniques and compare them 
with the histopathological findings. We identified ten studies for which the sensitivity 
and specificity were measured, and then we compared the data of our analysis with the 
meta-analysis data in the literature for ERUS [81]. Next, we combined our data with the 
met analysis data that found in the literature, and then pooling was conducted (using 
random-effects model). 
A random-effects model estimates the mean of a distribution of effects. We assume that 
each study estimates a unique effect, and we want to ensure that all these effect sizes are 
represented in the summary estimate. Study weights are more balanced under the 
random-effects model than under the fixed-effect model. Large studies are assigned less 
relative weight and smaller studies are assigned more relative weight as compared with 
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the fixed-effect model. Moreover under the random effects model there are two levels of 
sampling and two levels of error [95]. 
It is recommended in the meta-analysis of the diagnostic test accuracy that the results of 
the individual studies graph using the Receiver Operating Characteristic (ROC) show 
pairs of sensitivity and specificity values for the included studies, which are plotted as 
points in an ROC space that highlights the co-variation between sensitivity and 
specificity [94]. 
The ROC method is a complicated statistical approach and we preferred to present the 
data in the same manner as many published papers. Therefore in our systematic reviews 
we used Forrest plots that include the previous studies, which contained in the original 
systematic review plus the new studies that were found in our search. 
We obtained the sensitivity and specificity values for T1 and T2 for all the included 
articles; ERUS shows a sensitivity of (81%) and a specificity of (89%) for pT1, with a 
higher risk of over-staging than under-staging. For T2 the sensitivity was (78%) and a 
good specificity of (90%). With regard to the values of sensitivity and specificity, our 
analysis shows lower values than the Puli analysis [81] for stages T1 and T2. 
Forrest plots were drawn to show the point estimates in each study in relation to the 
summary pooled estimate. The accuracy of ERUS from the combined analysis showed 
the pooled estimates of sensitivity for T1 were 84% (95% confidence interval (CI) 0.75 to 
0.91) and for the specificity they were 93 % (95% CI 0.86 to 0.97), whereas for T2 the 
sensitivity was 83% (95% confidence interval (CI) 0.74 to 0.90) and the specificity was 
93% (95% CI 0.86 to 0.97). 
Our analysis shows that ERUS has very good diagnostic performance in staging early 
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rectal cancer (T) stage. 
If we look at each result of the included articles in our studies, we notice that the study by 
Fernandez showed that ERUS has a better resolution in early rectal cancer diagnosis, 
which is a potential advantage in supporting the use of TEM. 
For T1 the sensitivity of ERUS was 89% and the specificity 96%, while for T2 the 
sensitivity was 50% and the specificity 83% with regard to lymph node (N) staging. The 
accuracy of MRI was greater than ERUS, while its distinction was not statistically 
significant. Over-staging in T1 was found by ERUS in one patient and no under-staging, 
although in T2 rectal cancer there was over-staging in seven patients and under-staging in 
two patients [83].  
In addition, ERUS has been found to provide significant information. Yimei et al. [84] 
reported that ERUS had 87% greater sensitivity in T1 and 97% higher specificity in T2; 
with an accuracy of 83% for over-staging and 8.3% for under-staging. The majority of 
the studies included in this analysis were either retrospective or perspective and 
consecutive, and they recommend that T1 patients undergo ERUS to prevent unnecessary 
TME, additionally, the overall QUADA2 assessment for all the included studies were 
good. 
Another analysis by Mondel [86] indicates that ERUS is highly accurate in diagnosing 
the T-stage of early rectal cancer; it can differentiate between T1 tumors and T2 tumors 
that are invading the muscularis propria, with accuracy of between 69 and 97%, and a 
sensitivity of 90%. ERUS is the only imaging technique that has the ability to distinguish 
all five layers of the bowel wall, which allows the selection of patients for TEM.  
Patel et al. [87] evaluated patients by ERUS during two time periods. The sensitivity and 
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specificity for recognizing whether a lesion was confined to the mucosa or submucosa 
were	  70.8% and 100%, respectively. He also documented an increase in accuracy (73.1% 
to 78.3%) and a reduction in over-staging (26.9% to 21.7%). The sensitivity varied from 
(70.8% to 77.3%) for the initial period and after two years, while the specificity remained 
at 100% for both the initial period and after two years.  
The results obtained by J. Li [91] sowed that accuracy rate by ERUS for detecting the 
depth of a rectal tumor’s invasion is 86 to 92%. ERUS is an easy procedure to learn, with 
no radiation exposure and negligible discomfort for patients, as well as practically zero 
morbidity. Over-staging by REUS happens more commonly than under-staging at a rate 
of 10% vs. 4%. The first reason is inflammation around a tumor, which cannot be 
differentiated from malignant tissue by ERUS due to hypoechoic presentation, and 
second, performing a biopsy before ERUS can lead to over-staging. Li stated that the 
accuracy of nodal staging by ERUS was 66%, with a sensitivity of 73.9% and a 
specificity of 59.3%. 
Accordingly, it is worth doing ERUS in order to have better utility with fewer 
complications and recurrence rates. It also plays a role in accurately staging early rectal 
cancer. Shiyong Lin et al. [85] concluded that ERUS is safe and effective for preoperative 
staging of rectal cancer and should be a routine examination before surgery. The overall 
accuracy of ERUS T-staging was 86.5%, and the accuracy rates for T1 and T2 were 
86.7% and 94.0 %, respectively. No over-staging was found in T1, while T2 had over-
staging in two patients.  
Over staging occurs due to a peritumoral inflammatory reaction that results from 
preoperative biopsies, which cannot be distinguished by ERUS from the tumor itself, 
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while understaging occurs mainly from a failure to detect microscopic cancer infiltration.  
A longer period between the ERUS and the histopathology will lead to a change in the 
disease status and decrease in the biased power of the diagnostic test. 
Over staging by ERUS may lead to over treating of rectal cancer, which would typically 
need endoscopic resection, and as a result of this it will increase the rate of complications 
and affect the outcome.  
Zorcolo et al. [92] assessed the accuracy of ERUS for early-stage rectal cancer and 
determined that it is useful in anticipating the depth of invasion. The results revealed that 
small lesions limited to the submucosa have a small chance of nodal metastases and can 
be treated locally with an ERUS sensitivity of 96 %, a specificity of 85%, and 94% 
accuracy. Seven patients (36.8%) were over-staged preoperatively. 
ERUS is an effective and reliable method in detecting the depth of invasion of rectal 
tumors (T-staging), and if ERUS could diagnose T1 stage rectal cancers, 95% of which 
were later confirmed pathologically, this would assist physicians in proposing treatments 
with their confidence based on the ERUS staging of rectal cancer. The sensitivity, 
specificity, overall accuracy rate, PPV, and NPV of ERUS for pT1 were 86%, 95.6%, 
91.3%, 94.9%, and 88.7%, respectively. A specificity of 88.2% for T1, was observed by 
David Ravizza [88]. 
ÜNSAL et al. [90] showed that endoscopic rectal ultrasonography had 80.6% accuracy, 
93.4% sensitivity, and 96.5% specificity in T-stage. It is a really effective and reliable 
method in detecting the depth of invasion of rectal tumors (T-staging). 
In a study by Surace et al. [84] endoscopic rectal ultrasonography had 93.4% sensitivity 
and 96.5% specificity in T-stage, with a high risk of over-staging (47%) and a low risk of 
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under-staging for T2 (11%). The sensitivity and specificity for pT2 stage are 83% and 
91%, respectively.  
For the diagnostic accuracy reviews we used the modified version of the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool [78,79]. This assesses the 
quality of included studies in terms of risk of bias and concerns regarding applicability 
over four domains. Most of the studies in the literature evaluating the T-staging of rectal 
cancers had similar scores, and the majority of the included studies had a high quality 
score. 
The use of ERUS for T-staging was an easy procedure to acquire for accurate tumor 
staging, but identifying lymph nodes by ERUS is frequently challenging. Lymph node is 
important in staging but ERUS has lower accuracy in evaluating nodal metastases 
because it requires extensive skill and experience to achieve accuracy in nodal staging 
[90]. The accuracy of ERUS in predicting lymph nodes in the literature ranges from 70-
75% [83] . 
Puli et al. [81] looked at the accuracy of ERUS for the nodal involvement in the meta 
analysis, and showed that more than 2000 patients underwent ERUS for the diagnosis of 
nodal metastasis in rectal cancer with a sensitivity of 73 % and a specificity of 75.8%. 
In summary, this review of the diagnostic accuracy of ERUS techniques in early rectal 
cancer staging provides an example where there is some convincing evidence of the 
benefits of intervention. The good quality of the ERUS resolution in early rectal cancer is 
consistent with the findings of other studies.  
We have learned that ERUS is very useful in clinical assessment and is considered one of 
the most used methods for identifying appropriate T stage (T1-T2) in early rectal cancer. 
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This is deemed an advantage as it will help clinicians determine whether rectal tumors 
can be resected by endoscopic resection (TEM), rather than open surgery, and therefore, 
result in fewer complications. 
As a further step, this could be done in future research, to use patients’ level data from 
the Centre hospitalier de l'Université de Montréal (CHUM), and combine clinical and 
administrative databases in order to evaluate the utility of ERUS. We could also carry out 
an economic evaluation to determine whether ERUS is cost-effective. 
 
6.2-Strengths and limitations 
It is more challenging to perform diagnostic test accuracy reviews, because they are 
limited by the availability of test accuracy studies that address important and relevant 
questions. Moreover, further improvements are needed in terms of interpreting and 
presenting the results of diagnostic test accuracy reviews [Mariska M.G. Leeflang] [94]. 
This review has several strengths; we used a wide-ranging search strategy on numerous 
databases, and identified studies that compare ERUS diagnostic tests with histopathology. 
Two review author’s evaluated selected full studies for their inclusion. 
Several trials included consecutive patients to avoid selection bias. In another study the 
cohort of patients was a carefully selected group because the indication for ERUS was to 
assess their lesions’ suitability for local excision. 
Furthermore, in several studies ultrasound scans were performed by only two operators, 
which helped minimize any bias due to a combination of reports written by different 
operators. 
Nevertheless, numerous limitations should be expected in this review. 
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Some studies have a small number of pT1, which reflects the high incidence of T2 stages 
at diagnosis. 
The learning curve for orientation, interpretation, and precise probe positioning by an 
experienced operator can yield good results, however in this review there was an article 
That showed the responsible for ERUS could only estimate his accuracy in ERUS staging 
after surgical resection and reevaluate the ERUS images retrospectively to improve his 
accuracy rate, which limited the chance of achieving a rapid learning curve of the 
procedure, and subsequently limiting the results of this study. 
The ERUS we used were from various manufacturers and had different MHz frequencies. 
The procedure is highly operator dependent and cannot be performed on stenotic tumors 
due to the limited depth of the ERUS diffusion; to avoid this we could use catheter probe 
ERUS with a standard endoscope, which helps obtain accurate tumor staging in cases of 
malignant stenosis. 
An additional limitation of ERUS in one trial was the difficulty distinguishing between a 
malignant and inflammatory process. Both are monitored as irregular bordered and hypo 
echoic, which affects the precision of ERUS [90]. 
The heterogeneity depends on the clinical and methodological differences within the 
trials, and the studies included in the systematic review will certainly be different. 
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6.3- Sources of bias  
When conducting systematic reviews, several sources of bias should be identified and 
investigated in terms of how they effect the assessments of diagnostic test accuracy. 
These biases include: publication bias; heterogeneity; spectrum bias, information and 
verification bias. 
We performed a comprehensive literature search of several databases providing a 
complete systematic review of the current evidence on this subject to minimize the 
possibility of publication bias. 
There was no spectrum bias as all the patients included were representative of the 
intended segment of the target condition, nor was there any information bias as the 
reference standard in all the included trials was interpreted without knowing the index 
test results. 
Verification bias was prevented as the reference standard correctly classified the patients 
with the target condition. 
However, there was some heterogeneity bias because the procedure was highly operator 
dependent and due to the different frequencies of the ultrasound probes from various 
manufacturers that were used in the included trials. 
The time interval between performance of diagnostic tests and the reference test should 
be short. The time elapsed between test and surgery was not described in some studies, 
which may lead to Potential bias. 
 
	  	  	  
Chapter 7:                                      
                                                    Conclusion  
Implications for practice 
We evaluated 49 studies that compared endorectal ultrasonography (ERUS) with 
postoperative histology staging. Our results indicate that ERUS has good sensitivity and 
specificity, and provides more accurate staging for T1 and T2 lesions, which assists 
physicians in proposing simple operations, and leads to less pain for early stage rectal 
cancer. 
The reliability of the preoperative T-staging and postoperative pathological results was 
significantly consistent, therefore ERUS is recommended to be used as a tool to 
determine T-stage by directly imaging the layers of the rectal wall and the contiguous 
organs, and selecting the appropriate CRC treatment.  
Correct diagnosis and appropriate treatment is expected to improve clinical outcomes and 
to prevent patients from undergoing further invasive surgical procedures such as trans-
abdominal resection. 
We can conclude that ERUS is a practical, available, and accurate tool that can be used in 
the local staging of rectal cancers. However, in order to achieve the accuracy required an 
appropriate learning curve is needed for the orientation and identification of images, as 
well as significant experience to achieve accuracy for T and nodal staging. 
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Implications for research 
This review shows that the question of the diagnostic accuracy of ERUS in staging early 
rectal cancer in the patients included in these selected trials should now be considered 
answered.  
Further advancement in this technology will lead to improved diagnosis, staging, and 
clinical decision-making, and will reduce the drawback of over-staging. 
This review highlights the need for more trials to allow for a solitary test in order to 
provide complete and accurate staging information in people diagnosed with early rectal 
cancer. 
Further analyses will be required to address the cost-effectiveness of these tests, as well 
as their impact on patients’ overall outcome. 
Future research is needed in the analysis and presentation of the results of diagnostic test 
accuracy reviews. 
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Appendix A-Legends  	  
A.1. Ovid Medline  
1 Rectal Neoplasms/ (37408)  
2 exp early diagnosis/ (34745)  
3 Neoplasm Staging/ (143903)  
4 Neoplasm Grading/ (11479)  
5 or/2-4 (183508)  
6 1 and 5 (5109)  
7 Rectal Neoplasms/di, us (4966)  
8 (early and (rectal adj3 (cancer or neoplasm* or tumo?r*))).tw,kf. (1923)  
9 or/6-8 (10544)  
10 Endosonography/ (10436)  
11 (EUS or ERUS).tw,kf. (7140)  
12 ((endoscop* or endorectal or endo-rectal) adj3 (ultraso* or ultra-so*)).tw,kf. (10586)  
13 or/10-12 (18131)  
14 9 and 13 (752)  
15 Rectal Neoplasms/pa (12533)  
16 "Sensitivity and Specificity"/ (312149)  
17 "Predictive Value of Tests"/ (169556)  
18 validation studies/ (81552)  
	   ii	  
19 (histolog* or histopatholog* or patholog*).tw,kf. (1236891)  
20 or/15-19 (1707171)  
21 14 and 20 (604)  
22 limit 21 to (case reports or comment or editorial or letter) (75)  
23 21 not 22 (529)  
24 limit 23 to english language (424)  
25 limit 24 to yr="2009 -Current" (170)  
26 remove duplicates from 25 (165)  
 
A.2.Medline via PubMed 	  
Search  Query  Items found  
#9  Search (#7) AND #8  0  
#8  Search publisher[sb] NOT pmcbook  506095  
#7  Search (#5) AND #6  108  
#6  Search (histolog*[Text Word] OR 
histopatholog*[Text Word] OR patholog*[Text 
Word])  
3447213  
#5  Search (#1) AND #4  150  
#4  Search (#2) OR #3  22872  
#3  Search ((endoscop*[Text Word] OR 
endorectal[Text Word] OR endo-rectal[Text 
Word])) AND (ultraso*[Text Word] OR ultra-
so*[Text Word])  
20998  
#2  Search (EUS[Text Word] OR ERUS[Text 
Word])  
6817  
#1  Search ((rectal-cancer[Text Word] OR rectal-
neoplasm*[Text Word] OR rectal-tumor*[Text 
Word] OR rectal-tumour*[Text Word])) AND 
early[Text Word]  
3160  
Search	  	   Query  Items found  	  	  	  	  	  
	   iii	  
	  	  
A.3. Ovid Embase  
1 rectum cancer/ (28976)  
2 rectum carcinoma/ (12929)  
3 1 or 2 (38756)  
4 early diagnosis/ (108905)  
5 early cancer diagnosis/ (538)  
6 early cancer/ (14798)  
7 cancer staging/ (214683)  
8 cancer grading/ (52660)  
9 or/4-8 (365114)  
10 3 and 9 (7146)  
11 rectum cancer/di [Diagnosis] (2534)  
12 rectum carcinoma/di (1633)  
13 (early and (rectal adj3 (cancer or neoplasm* or tumo?r*))).tw,kw. (3256)  
14 or/10-13 (11900)  
15 endoscopic echography/ (23645)  
16 echography/ (280964)  
17 ultrasound/ (205490)  
18 16 or 17 (442305)  
19 (endorectal or endo-rectal).tw. (3086)  
	   iv	  
20 18 and 19 (919)  
21 ((endoscop* or endorectal or endo-rectal) adj3 (ultraso* or ultra-so*)).tw,kw. (17223)  
22 (EUS or ERUS).tw,kw. (14488)  
23 15 or 20 or 21 or 22 (34006)  
24 14 and 23 (923)  
25 "sensitivity and specificity"/ (265198)  
26 validation study/ (62003)  
27 diagnostic accuracy/ (210753)  
28 histopathology/ (439961)  
29 (histolog* or histopatholog* or patholog*).tw,kw. (1716855)  
30 or/25-29 (2293426)  
31 24 and 30 (628)  
32 limit 31 to (editorial or letter or note or report) (23)  
33 31 not 32 (605)  
34 limit 33 to english language (527)  
35 limit 34 to yr="2009 -current" (260)  
36 remove duplicates from 35 (254)  
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A.4. The Cochrane Library 	  
ID  SEARCH  HITS  
#1  (early and (rectal near/3 (cancer or neoplasm* 
or tumor* or tumour*))):ti,ab,kw  
167  
#2  (EUS or ERUS):ti,ab,kw  402  
#3  ((endoscop* or endorectal or endo-rectal) 
near/3 (ultraso* or ultra-so*)):ti,ab,kw  
496  
#4  #2 or #3  638  
#5  #5 #1 and #4  
Publication Year from 2009 to 2016  
1  	  
• DARE	  (to	  issue	  2	  of	  4,	  April	  2015):	  1	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B.1. Ovid Medline 
	  
	   vi	  
Subheadings are qualifiers added to a subject heading to refine the meaning. 	  
A complete list of subheadings is available at:  
 
http://ovidsupport.custhelp.com/app/answers/detail/a_id/2078/~/list-of-medline-
subheadings-and-their-codes 	  
B.2.PubMed Medline 
	  
	  
	  A	  complete	  list	  of	  subheadings	  is	  available	  at:	  http://ovidsupport.custhelp.com/app/answers/detail/a_id/2078/~/list-­‐of-­‐medline-­‐subheadings-­‐and-­‐their-­‐codes	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B.3. Ovid Embase	  
	  
Subheadings are qualifiers added to a subject heading to refine the meaning.  
A complete list of subheadings is available in the database field guide through Ovid. 
	  
B.4 The Cochrane Library 
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Appendix C: PRISMA-P 
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis 
Protocols) 2015 checklist: recommended items to address in a systematic review 
protocol*  
 
Section and topic Item 
No 
Checklist item 
ADMINISTRATIVE INFORMATION Title:	   	   	  	   Identification	   1a	   Identify	  the	  report	  as	  a	  protocol	  of	  a	  systematic	  review	  	   Update	   1b	   If	  the	  protocol	  is	  for	  an	  update	  of	  a	  previous	  systematic	  review,	  identify	  as	  such	  Registration	   2	   If	  registered,	  provide	  the	  name	  of	  the	  registry	  (such	  as	  PROSPERO)	  and	  registration	  number	  Authors:	   	   	  	   Contact	   3a	   Provide	  name,	  institutional	  affiliation,	  e-­‐mail	  address	  of	  all	  protocol	  authors;	  provide	  physical	  mailing	  address	  of	  corresponding	  author	  	   Contributions	   3b	   Describe	  contributions	  of	  protocol	  authors	  and	  identify	  the	  guarantor	  of	  the	  review	  Amendments	   4	   If	  the	  protocol	  represents	  an	  amendment	  of	  a	  previously	  completed	  or	  published	  protocol,	  identify	  as	  such	  and	  list	  changes;	  otherwise,	  state	  plan	  for	  documenting	  important	  protocol	  amendments	  Support:	   	   	  	   Sources	   5a	   Indicate	  sources	  of	  financial	  or	  other	  support	  for	  the	  review	  	   Sponsor	   5b	   Provide	  name	  for	  the	  review	  funder	  and/or	  sponsor	  	   Role	  of	  sponsor	  or	  funder	   5c	   Describe	  roles	  of	  funder(s),	  sponsor(s),	  and/or	  institution(s),	  if	  any,	  in	  developing	  the	  protocol	  
INTRODUCTION Rationale	   6	   Describe	  the	  rationale	  for	  the	  review	  in	  the	  context	  of	  what	  is	  already	  known	  Objectives	   7	   Provide	  an	  explicit	  statement	  of	  the	  question(s)	  the	  review	  will	  address	  with	  reference	  to	  participants,	  interventions,	  comparators,	  and	  outcomes	  (PICO)	  
METHODS Eligibility	  criteria	   8	   Specify	  the	  study	  characteristics	  (such	  as	  PICO,	  study	  design,	  setting,	  time	  frame)	  and	  report	  characteristics	  (such	  as	  years	  considered,	  language,	  publication	  status)	  to	  be	  used	  as	  criteria	  for	  eligibility	  for	  the	  review	  Information	  sources	   9	   Describe	  all	  intended	  information	  sources	  (such	  as	  electronic	  databases,	  contact	  with	  study	  authors,	  trial	  registers	  or	  other	  grey	  literature	  sources)	  with	  planned	  dates	  of	  coverage	  Search	  strategy	   10	   Present	  draft	  of	  search	  strategy	  to	  be	  used	  for	  at	  least	  one	  electronic	  database,	  including	  planned	  limits,	  such	  that	  it	  could	  be	  repeated	  Study	  records:	   	   	  	   Data	  management	   11a	   Describe	  the	  mechanism(s)	  that	  will	  be	  used	  to	  manage	  records	  and	  data	  throughout	  the	  review	  
	   ix	  
	   Selection	  process	   11b	   State	  the	  process	  that	  will	  be	  used	  for	  selecting	  studies	  (such	  as	  two	  independent	  reviewers)	  through	  each	  phase	  of	  the	  review	  (that	  is,	  screening,	  eligibility	  and	  inclusion	  in	  meta-­‐analysis)	  	   Data	  collection	  process	   11c	   Describe	  planned	  method	  of	  extracting	  data	  from	  reports	  (such	  as	  piloting	  forms,	  done	  independently,	  in	  duplicate),	  any	  processes	  for	  obtaining	  and	  confirming	  data	  from	  investigators	  Data	  items	   12	   List	  and	  define	  all	  variables	  for	  which	  data	  will	  be	  sought	  (such	  as	  PICO	  items,	  funding	  sources),	  any	  pre-­‐planned	  data	  assumptions	  and	  simplifications	  Outcomes	  and	  prioritization	   13	   List	  and	  define	  all	  outcomes	  for	  which	  data	  will	  be	  sought,	  including	  prioritization	  of	  main	  and	  additional	  outcomes,	  with	  rationale	  Risk	  of	  bias	  in	  individual	  studies	   14	   Describe	  anticipated	  methods	  for	  assessing	  risk	  of	  bias	  of	  individual	  studies,	  including	  whether	  this	  will	  be	  done	  at	  the	  outcome	  or	  study	  level,	  or	  both;	  state	  how	  this	  information	  will	  be	  used	  in	  data	  synthesis	  Data	  synthesis	   15a	   Describe	  criteria	  under	  which	  study	  data	  will	  be	  quantitatively	  synthesised	  15b	   If	  data	  are	  appropriate	  for	  quantitative	  synthesis,	  describe	  planned	  summary	  measures,	  methods	  of	  handling	  data	  and	  methods	  of	  combining	  data	  from	  studies,	  including	  any	  planned	  exploration	  of	  consistency	  (such	  as	  I2,	  Kendall’s	  τ)	  15c	   Describe	  any	  proposed	  additional	  analyses	  (such	  as	  sensitivity	  or	  subgroup	  analyses,	  meta-­‐regression)	  15d	   If	  quantitative	  synthesis	  is	  not	  appropriate,	  describe	  the	  type	  of	  summary	  planned	  Meta-­‐bias(es)	   16	   Specify	  any	  planned	  assessment	  of	  meta-­‐bias(es)	  (such	  as	  publication	  bias	  across	  studies,	  selective	  reporting	  within	  studies)	  Confidence	  in	  cumulative	  evidence	   17	   Describe	  how	  the	  strength	  of	  the	  body	  of	  evidence	  will	  be	  assessed	  (such	  as	  GRADE)	  
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P 
Explanation and Elaboration (cite when available) for important clarification on the items. 
Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P 
(including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons 
Attribution Licence 4.0.  
 
From:	  Shamseer	  L,	  Moher	  D,	  Clarke	  M,	  Ghersi	  D,	  Liberati	  A,	  Petticrew	  M,	  Shekelle	  P,	  Stewart	  L,	  PRISMA-­‐P	  
Group.	  Preferred	  reporting	  items	  for	  systematic	  review	  and	  meta-­‐analysis	  protocols	  (PRISMA-­‐P)	  2015:	  
elaboration	  and	  explanation.	  BMJ.	  2015	  Jan	  2;349(jan02	  1):g7647.	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Appendix D – Data extraction  
 	  Study characteristic table 	  
Title, Author 
 
	  
Year of Publication 
 
	  
Study design 
 
	  
Confirmatory procedure  
 
	  Population	  characteristics  
 
	  
Intervention exposure 
 
	  
Setting (practice, hospital) 
 
	  
Outcome 
 
 
 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix E  
Figure 2:PRISMA flow diagram 
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Appendix F - Quality Assessment Tool QUADAS-2 
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QUADAS-2 tool: Risk of bias and applicability judgments  :Glòria Fernández-
Esparrach 
Domain 1: Patient selection 
A. Risk of bias  
Describe methods of patient selection: All	  consecutive	  patients	  evaluated	  in	  the	  Departments	  of	  Gastroenterology	  and	  Surgery	  were	  asked	  to	  participate	  in	  this	  prospective	  investigation	  if	  they	  met	  one	  of	  the	  following	  inclusion	  criteria:	  (1)	  histologically	  proven	  rectal	  cancer	  and	  (2	  written	  informed	  consent	  
 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Patients with histology proven rectal cancer, with written consent. 
 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
A. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
EUS and MRI were performed in all patients 
 
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
A. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
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Pathological	  examination	  was	  done	  without	  knowledge	  of	  the	  results	  of	  EUS	  and	  MRI,	  preventing	  an	  overestimation	  of	  the	  tests’	  accuracy.	  The	  surgical	  specimen	  was	  staged	  (TNM)	  according	  to	  the	  guidelines	  of	  the	  American	  Joint	  Committee	  on	  Cancer	  
 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
A. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
 
 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
 
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
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• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
 	  QUADAS-­‐2	  tool:	  The learning curve for endorectal ultrasonography in rectal 
cancer staging 
 Jimmy C. M. Li 	  
Domain 1: Patient selection 
C. Risk of bias  
Describe methods of patient selection: Preoperative	  ERUS	  was	  performed	  on	  consecutive	  patients	  with	  rectal	  cancer	  
to evaluate local tumor and nodal staging in our uni 
 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
D. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Patients with histology proven rectal cancer, with written consent. 
 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
C. Risk of bias  
Describe the index test and how it was conducted and interpreted: All	  ERUS	  examinations	  were	  conducted	  as	  a	  day-­‐case	  procedure	  either	  concurrently	  with	  diagnostic	  colonoscopy	  or	  separately	  after	  rectal	  cancer	  had	  been	  diagnosed	  by	  prior	  colonoscopy	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
D. Concerns regarding applicability  
Is there concern that the index test, its conduct, or CONCERN: 
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interpretation differ from the review question? LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
C. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
After ERUS and other relevant preoperative evaluation, all rectal resections were 
performed within 3 weeks of ERUS.Histopathological examination was then conducted in 
all resected specimens. The 6th American Joint Committee on Cancer (AJCC) 
classification was adopted as the histopathological 
staging system used in this study (pTNM) 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
D. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
B. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
 
In the 26-month study period, 92 patients with primary rectal carcinoma underwent 
preoperative ERUS staging. Forty-two patients were excluded from the study due to use 
of neoadjuvant chemoradiation (n =  18), no subsequent surgery performed (n =  21), or 
failed examination(n =  3). Reasons for failed examination included stenotic tumors in 
two patients and balloon failure in one patient.All three of these patients underwent 
curative resection, 
and their respective pathological stages were either T3N0 or T2N0. Fifty patients who 
had surgery without neoadjuvant chemoradiation were included for final analysis.	   
Describe the time interval and any interventions between index test(s) and reference 
standard: 
at least 3 weeks of ERUS 
 
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
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LOW/HIGH/UNCLEAR 
 	  
 QUADAS-­‐2	  tool:	  Application of Endoscopic Sonography in Preoperative Staging of 
Rectal Cancer 
Shiyong Lin, PhD,	  
Domain 1: Patient selection 
E. Risk of bias  
Describe methods of patient selection: rectal	  cancer	  confirmed	  by	  histopathologic	  evaluation	  of	  endoscopic	  biopsy	  samples	  
were included in the study retrospectively 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
F. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Patients with histology proven rectal cancer, with written consent. 
 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
E. Risk of bias  
Describe the index test and how it was conducted and interpreted: the	  endoscopic	  sonographic	  examination	  was	  performed	  1	  to	  3	  weeks	  before	  surgery.	  The	  endoscopic	  sonography	  system	  had	  4	  ultrasonic	  frequency	  choices	  (5,	  7.5,	  12,	  and	  20	  MHz)	  for	  detecting	  different	  lesion	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
F. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
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E. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
All patients in this study underwent surgical resection for rectal lesions, and the resected 
specimens were totally subjected to histopathologic evaluation. The specimens were prepared 
conventionally at the Department of Pathology in our hospital. Both gross inspection and 
microscopic evaluation were carefully done by certified pathologists. All lesions were staged 
according to the guidelines of the Union for International Cancer Contro 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
F. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
C. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
unclear 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
performed 1 to 3 weeks before surgery. 
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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QUADAS-2 tool:  	  How useful is endorectal ultrasound in the management of early 
rectal carcinoma? 
D. Mondal  
Domain 1: Patient selection 
G. Risk of bias  
Describe methods of patient selection: 
 	  Patients with adenomas/early rectal carcinoma being considered for TEM were 
prospectively studied 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
H. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Patients with adenomas or early rectal carcinoma, who were being considered for TEM at 
a tertiary referral centre in Oxford, were prospectively studied during a 2-year period 
(mid-July 2011 to mid-July 2013) 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
G. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
Each patient underwent an endorectal ultrasound investigation as part of their normal 
care performed by one of two consultant GI radiologists with 7 years experience in 
endorectal sonography. The images were reviewed by both radiologists, and the report 
was a consensus 
opinion	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
H. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
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G. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
Comparison was also made between the ultrasound stage and the final pathological stage 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
H. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
D. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): Ninety-­‐six	  patients	  were	  referred	  for	  staging	  of	  rectal	  neoplasiaover	  2	  years.	  Nine	  were	  out	  of	  reach	  of	  the	  rigid	  probe	  andwere	  excluded.	  Of	  the	  remainder,	  proformas	  were	  completedon	  53..	  Forty-­‐eight	  patients	  had	  a	  final	  pathological	  report	  on	  a	  surgical	  specimen	  to	  compare	  with	  the	  T	  stage	  of	  the	  ultrasound.	  
Ultrasound agreed with the pathological T staging in 43 patients. 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
unclear	  
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
 	  
 
 
 
 
 
 
	   xxii	  
QUADAS-2 tool:  
	  The Role of Endorectal Ultrasound and Magnetic Resonance Imaging in the 
Management of Early Rectal Lesions in a Tertiary Center 
Rikesh Kumar Patel, 
Domain 1: Patient selection 
I. Risk of bias  
Describe methods of patient selection: 
 	  Data	  collection	  and	  analysis	  was	  performed	  by	  2	  colorectal	  research	  fellows	  .	  They	  reviewed	  the	  :	  macroscopic	  appearance	  at	  colonoscopy,	  histopathological	  examination	  of	  biopsies,	  depth	  of	  invasion	  determined	  using	  MRI	  and	  ERUS,	  surgical	  procedure	  undertaken,	  and	  final	  histopathological	  examination	  of	  the	  excised	  lesion 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
J. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): Retrospective	  analysis	  of	  a	  prospectively	  maintained	  database	  of	  patients	  who	  underwent	  ERUS	  was	  carried	  out	  over	  an	  initial	  25-­‐month	  period	  at	  a	  tertiary	  colorectal	  center.	  
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
I. Risk of bias  
Describe the index test and how it was conducted and interpreted: Patients	  investigated	  with	  ERUS	  and	  MRI	  before	  local	  excision	  or	  formal	  resection	  were	  identified	  from	  a	  prospectively	  maintained	  database	  at	  a	  UK	  tertiary	  colorectal	  center	  over	  a	  25-­‐month	  period	  . 
 
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
J. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
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I. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: Local	  excision	  should	  be	  considered.	  Salvage	  surgery	  can	  be	  carried	  out	  if	  the	  subsequent	  histopathology	  reveals	  the	  lesion	  to	  have	  adverse	  oncological	  features.	  
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
J. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
E. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): A	  65	  patients	  underwent	  ERUS.	  Patients	  were	  excluded	  for	  the	  following	  reasons:	  received	  O	  neoadjuvant	  therapy	  (n	  .	  7);	  managed	  with	  endoluminal	  contact	  radiotherapy	  (n	  .	  4);	  and	  treated	  at	  other	  institutions	  (n	  .	  2).	  In	  total,	  52	  were	  identified	  as	  having	  undergone	  assessment	  of	  a	  rectallesion	  with	  ERUS	  who	  had	  not	  received	  neoadjuvant	  therapy	  for	  whom	  histology	  after	  resection	  was	  available.	  	  Over	  the	  subsequent	  12-­‐month	  period,	  27	  patients	  underwent	  ERUS	  with	  4	  patients	  excluded	  for	  the	  following	  reasons:	  managed	  with	  endoluminal	  contact	  radiotherapy	  (n	  .	  1);	  and	  treated	  at	  other	  institutions	  (n	  .	  3).	  The	  median	  age	  of	  the	  included	  patients	  was	  69	  (range,	  39-­‐83)	  years	  over	  the	  2	  Study Periods in Defining Lesions Suitable for Local Excision	  
 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
unclear	  
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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QUADAS-2 tool:  
Linear array ultrasonography to stage rectal neoplasias suitable for local 
treatment 
Davide Ravizza∗ , 
Domain 1: Patient selection 
K. Risk of bias  
Describe methods of patient selection: 
 	  The	  study	  population	  consisted	  of	  92	  patients	  with	  92	  neoplasias	  (68	  adenocarcinomas	  and	  24	  adenomas).	  A	  5	  and	  7.5	  MHz	  linear	  array	  echoendoscope	  was	  used.	  The	  postoperative	  histopathologic	  result	  was	  compared	  with	  the	  preoperative	  staging	  defined	  by	  endorectal	  ultrasonography.	  Adenomas	  	  and	  cancers	  limited	  to	  the	  submucosa	  were	  considered	  together	  (pT0–1).	  
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
L. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): The	  population	  of	  this	  retrospective	  observational	  study	  was	  obtained	  by	  considering	  all	  the	  patients	  with	  rectal	  neoplasia	  (adenomas	  and	  primary	  adenocarcinomas	  located	  within	  15	  cm	  from	  the	  anal	  verge)	  who	  were	  staged	  by	  ERUS	  from	  January	  2001	  to	  March	  2010	  at	  the	  Division	  of	  Endoscopy	  of	  the	  European	  Institute	  of	  Oncology	  of	  Milan.	  
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
K. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
 All	  the	  ERUSs,	  in	  all	  cases	  preceded	  by	  an	  endoscopic	  evaluation	  were	  performed	  
by two operators. 
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
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L. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
K. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: ERUS	  stages	  were	  compared	  with	  the	  histopathological	  examination	  (pT	  and	  pN),	  the	  reference	  gold	  standard.	  Concerning	  the	  T	  parameter,	  only	  patients	  with	  both	  ERUS	  and	  histopathological	  
examinations were enrolled. 
 
• Is the reference standard likely to correctly classify the 
target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its interpretation 
have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
L. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
F. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
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Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
Unclear	  
• Was there an appropriate interval between index test(s) 
and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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QUADAS-2 tool:  
Endorectal ultrasound in the diagnosis of rectal cancer: Accuracy and 
criticies 
Alessandra Surace 
Domain 1: Patient selection 
M. Risk of bias  
Describe methods of patient selection: 
 	  77	  reports	  ultrasound	  with	  the	  final	  diagnosis	  of	  rectal	  cancer	  from	  the	  period	  2008e2012	  were	  examined.	  The	  echographies	  were	  performed	  by	  two	  experienced	  operators,	  using	  two	  ultrasound	  device	  with	  the	  same	  technical	  characteristics.	  
 
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
N. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): The	  population	  of	  this	  retrospective	  observational	  study	  was	  obtained	  by	  considering	  all	  the	  patients	  with	  rectal	  neoplasia	  (adenomas	  and	  primary	  adenocarcinomas	  located	  within	  15	  cm	  from	  the	  anal	  verge)	  who	  were	  staged	  by	  ERUS	  from	  January	  2001	  to	  March	  2010	  at	  the	  Division	  of	  Endoscopy	  of	  the	  European	  Institute	  of	  Oncology	  of	  Milan.	  
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
M. Risk of bias  
Describe the index test and how it was conducted and interpreted: The	  echographies	  were	  performed	  by	  two	  experienced	  operators	  as	  defined	  in	  the	  literature	  coming	  from	  the	  same	  school	  and	  with	  identity	  setting	  and	  reporting:	  they	  collaborated	  for	  five	  years	  and	  for	  one	  year	  compared	  to	  blind	  their	  reports.	  The	  ultrasound	  used	  in	  the	  two	  centers	  are	  identical	  and	  use	  a	  radial	  probe	  at	  a	  frequency	  of	  10e13	  MHz.	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
N. Concerns regarding applicability  
	   xxviii	  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
M. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: Characteristics	  of	  ERU	  accuracy	  were	  estimated	  by	  comparing	  ultrasound	  report	  with	  the	  pathological	  findings,	  considered	  the	  gold	  standard;	  for	  staging	  TNM	  classification	  was	  used	  
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
N. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
G. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
 On	  130	  patients	  operated,	  117	  are	  staged	  with	  the	  ERU.	  Only	  exclusion	  criteria	  was	  the	  treatment	  with	  neoadjuvant	  therapy;	  applying	  this	  limit,	  the	  patients	  included	  in	  the	  study	  were	  77	  
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
Unclear	  
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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QUADAS-2 tool:  
The efficacy of endoscopic ultrasonography in local staging of rectal tumors 
Belk›s ÜNSAL 
Domain 1: Patient selection 
O. Risk of bias  
Describe methods of patient selection: 
 This	  retrospective	  study	  was	  carried	  out	  by	  the	  Department	  of	  Gastroenterology,	  ‹zmir	  Atatürk	  Training	  and	  Research	  Hospital,	  which	  is	  tertiary	  level.	  Thirty-­‐one	  patients	  with	  adenocarcinoma	  were	  included	  in	  the	  study.	  The	  patients	  found	  operable	  according	  to	  computed	  tomography	  underwent	  preoperative	  local	  staging	  by	  endoscopic	  ultrasonography.	  Radial	  endoscopic	  ultrasonography	  and	  T	  and	  N	  stages	  were	  evaluated	  
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
P. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): Thirty-­‐one	  consecutive	  patients	  with	  resectable	  rectal	  carcinoma	  were	  recorded	  from	  June	  2009	  to	  November	  2010	  Rectal	  carcinoma	  was	  confirmed	  by	  histologic	  analysis	  of	  endoscopic	  biopsy	  samples,	  and	  it	  was	  considered	  that	  the	  rectal	  site	  extended	  from	  the	  anal	  verge	  to	  the	  rectosigmoid	  junction.	  The	  patients	  who	  previously	  underwent	  emergency	  surgery,	  chemotherapy	  or	  radiotherapy	  were	  excluded.	  
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
O. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
 EUS	  examinations	  were	  performed	  using	  a	  Hitachi	  EUB-­‐7000	  Ultrasonography	  plus	  Pentax	  radial	  360°	  probe	  (7.5-­‐10	  MHz)	  (Pentax	  FG36UX	  ultrasound	  ultrasoundscanner;	  Pentax	  Precision	  Instruments,	  NewYork,	  NY).	  The	  examinations	  were	  conducted	  on	  the	  patient	  in	  a	  left	  lateral	  decubitus	  position	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have RISK: 
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introduced bias? LOW/HIGH/UNCLEAR 
P. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
O. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: The	  surgical	  specimen	  was	  subjected	  to	  full	  pathologic	  examination	  and	  staged	  (TNM)	  in	  accordance	  with	  the	  guidelines	  of	  the	  American	  Joint	  Committee	  on	  Cancer.	  Histological	  evaluations	  were	  carried	  out	  by	  two	  pathologists 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
P. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
H. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
42	  patients	  included,	  11	  patients	  were	  inoperable,	  and	  these	  patients	  were	  not	  included	  in	  the	  study.	  histological	  parameters	  obtained	  from	  the	  surgical	  materials	  of	  the	  other	  31	  patients	  were	  compared	  
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
14-17 days	  
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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QUADAS-2 tool:  
A comparison between the reference values of MRI and EUS and their usefulness to 
surgeons in rectal cancer 
J. YIMEI, Z. 
Domain 1: Patient selection 
Q. Risk of bias  
Describe methods of patient selection: 	  From	  January	  to	  December	  2011,	  patients	  with	  proven	  histological	  primary	  rectal	  cancer	  and	  evaluated	  in	  the	  Departments	  of	  Surgery,	  Gastroenterology,or	  Radiology	  were	  considered	  for	  enrollment	  in	  the	  study,	  all	  consecutive	  patients	  	  
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
R. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): Patients	  Underwent	  colonoscopy	  and	  biopsy	  that	  proved	  rectal	  cancer;	  2)	  no	  evidence	  of	  metastasis	  from	  CT;	  (3)	  underwent	  MRI	  or	  EUS	  staging;	  (4)	  first	  time	  being	  diagnosed;(5)	  resectable	  and	  had	  surgery	  in	  our	  Hospital;	  (6)	  written	  informed	  consent.	  Also,	  they	  must	  not	  have	  met	  and	  of	  the	  exclusion	  criteria 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
Q. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
 
EUS was performed with a 360-degree radial echo-endoscope 
(Fujinon EG400, Fujinon Corp., Tokyo, Japan) and a 15MHz high-frequency ultrasound 
probe (SP-701, SP-702). The operators were senior gastroenterology physicians that 
facilitated in diagnosis and staging of rectal cancer. 
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
R. Concerns regarding applicability  
Is there concern that the index test, its conduct, or CONCERN: 
	   xxxii	  
interpretation differ from the review question? LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
Q. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: Results	  for	  T,	  N,	  and	  TN	  staging	  at	  both	  MRI	  and	  EUS	  were	  compared	  with	  histopathological	  staging	  of	  the	  surgical	  specimen,	  which	  was	  the	  reference	  standard	  (refer	  to	  AJCC	  Cancer	  Staging	  Manual	  H201020 
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
R. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
I. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 202	  met	  the	  inclusion	  criteria.	  Of	  these,	  63	  were	  excluded	  because	  of	  one	  or	  more	  exclusion	  criteria.	  	  The	  final	  study	  population	  consisted	  of	  129	  consecutive	  patients	  
 
 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 
14-17 days	  
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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 QUADAS-­‐2	  tool:	  Preoperative staging of patients with rectal tumors suitable 
for transanal endoscopic microsurgery (TEM): comparison 
of endorectal ultrasound and histopathologic findings 
 Luigi Zorcolo 
Domain 1: Patient selection 
S. Risk of bias  
Describe methods of patient selection: Demographics,	  preoperative,	  operative,	  and	  postoperative	  data	  were	  prospectively	  collected	  into	  an	  electronic	  database.	  Preoperative	  evaluation	  was	  always	  carried	  out	  by	  the	  surgeon	  deemed	  to	  perform	  the	  operation	  and	  included	  clinical	  history,	  digital	  examination,	  complete	  colonoscopy	  with	  tumor	  biopsies,	  and	  rigid	  sigmoidoscopy	  to	  determine	  the	  exact	  distance	  from	  the	  anal	  verge	  and	  the	  position	  in	  the	  rectal	  wall.	  
• Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
• Was a case-control design avoided? Yes/No/Unclear 
• Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
T. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Patients with histology proven rectal cancer, with written consent. 
 
Is there concern that the included patients do not match the 
review question?  
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
S. Risk of bias  
Describe the index test and how it was conducted and interpreted: Local	  staging	  of	  the	  neoplasm	  was	  achieved	  by	  endorectal	  ultrasound	  (ERUS)	  with	  a	  10-­‐MHz	  rotating	  probe(anorectal	  probe	  type	  1850;	  BK	  Medical).	  
• Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
• If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
T. Concerns regarding applicability  
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
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Domain 3: Reference standard 
S. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: Histopathologic	  stage	  (pT)	  was	  then	  compared	  with	  preoperative	  stage	  (uT)	  in	  order	  to	  determine	  the	  accuracy	  of	  ERUS.	  
• Is the reference standard likely to correctly classify 
the target condition? 
Yes/No/Unclear 
• Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
T. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
J. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): Eighty-­‐eight	  patients	  underwent	  TEM	  ,	  Seven	  of	  them	  in	  whom	  ERUS	  was	  not	  performed	  	  and	  were	  excluded	  from	  this	  study.	  Of	  the	  remaining,	  there	  were	  46	  men	  and	  35	  women	  were	  included.	  
7 patients  excluded out of 81 patients 
 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
Unclear 
 
• Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
• Did all patients receive a reference standard? Yes/No/Unclear 
• Did patients receive the same reference standard? Yes/No/Unclear 
• Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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AMSTAR – a measurement tool to assess the methodological quality of systematic reviews. 
1. Was an 'a priori' design provided? 
The research question and inclusion criteria should be established before the conduct of 
the review. 
 
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published 
research objectives to score a “yes.”  
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
 
2. Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place. 
 
Note: 2 people do study selection, 2 people do data extraction, consensus process or one 
person checks the other’s work. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
 
3. Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms 
must be stated and where feasible the search strategy should be provided. All searches 
should be supplemented by consulting current contents, reviews, textbooks, specialized 
registers, or experts in the particular field of study, and by reviewing the references in 
the studies found. 
 
Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane 
register/Central counts as 2 sources; a grey literature search counts as supplementary). 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
 
4. Was the status of publication (i.e. grey literature) used as an inclusion 
criterion? 
The authors should state that they searched for reports regardless of their publication 
type. The authors should state whether or not they excluded any reports (from the 
systematic review), based on their publication status, language etc. 
 
Note: If review indicates that there was a search for “grey literature” or “unpublished 
literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and 
trial registries are all considered grey for this purpose. If searching a source that contains 
both grey and non-grey, must specify that they were searching for grey/unpublished lit.    
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
 
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to 
the list but the link is dead, select “no.” 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
 
6. Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should be provided 
on the participants, interventions and outcomes. The ranges of characteristics in all the 
studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, 
duration, severity, or other diseases should be reported. 
 
Note: Acceptable if not in table format as long as they are described as above. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
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